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ABSTRACT OF DISSERTATION 
 
 
 
 
 
A DIET ENRICHED IN STEARIC ACID PROTECTS AGAINST THE 
PROGRESSION OF TYPE 2 DIABETES IN LEPTIN RECEPTOR DEFICIENT MICE 
(DB/DB) 
Dietary saturated fat intake contributes to diabetes and cardiovascular disease, as shown 
in numerous animal and human studies. However, the hypothesis that stearic acid, a 
saturated fat, has beneficial effects on these conditions has not been adequately tested.  
Leptin receptor deficient mice (db/db) and wild-type mice were fed either chow or a high 
fat diet enriched in either stearic acid or oleic acid for ten weeks. The progression of 
diabetes was evaluated with blood glucose, insulin, and metabolic parameter 
measurements. At the conclusion of the study, pancreatic islet organization was 
examined, and blood, liver and feces were assayed for fatty acid content.  
The stearic acid enriched diet prevented increases in blood glucose levels independently 
of weight loss in db/db mice compared to an oleic acid or chow diet. Diabetic mice fed 
stearic acid maintained insulin responsiveness and pancreatic islet organization compared 
to the db/db mice fed chow and oleic diets. The islet organization of the stearic acid fed 
mice did not change over the course of the study and was similar to that of wild-type 
mice fed the same diet. Conversely, diabetic mice fed oleic acid and chow diets had 
decreased insulin responsiveness and disorganized islets. Stearic acid fed db/db mice had 
high fecal fat content and caloric intake calculations indicated low absorption of this fat.  
Switching to stearic acid after prolonged hyperglycemia had a rescue effect on blood 
glucose levels. After feeding diabetic and wild-type mice standard chow diets for 6, 8, 
and 10 weeks to establish hyperglycemia, mice switched to a high fat diet enriched in 
stearic acid, but not one enriched in oleic acid diet, had significant reductions in blood 
glucose levels. 
The ability of a stearic acid enriched high fat diet to slow the progression of diabetes and 
reverse hyperglycemia in db/db mice argues that risks and benefits of fats in the diet 
depend on the chemical structure, rather than the chemical class, of fats ingested. The 
beneficial effect of stearic acid appears to be associated with a decreased absorption of 
dietary fat. 
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1 
Chapter 1: Background 
1.1 Diabetes and obesity 
 Diabetes is a widespread disease affecting an estimated 23 million Americans, 
and according to the American Diabetes Association, only two thirds of these cases have 
been diagnosed (66). The majority of cases of diabetes are type 2 diabetes. Additionally, 
type 2 diabetes is now a worldwide disease. The World Health Organization estimated 
135 million people worldwide have diabetes in 2000, and the number of people with 
diabetes has been projected to reach over 300 million worldwide in the next ten years 
(105). The majority of new cases of type 2 diabetes will be in developing countries, and 
these new cases will double the current incidence of the disease (4). 
 The increased incidence of type 2 diabetes in developing countries begs the 
question, what is contributing to the onset of type 2 diabetes? One of the leading risk 
factors for developing type 2 diabetes is obesity. Similar to the increased incidence of 
diabetes, the incidence of obesity is also dramatically increasing. From 1976 to 1994, 
obesity in the United States has increased 8% and statistical projections predict future 
increases (19, 62). These increases align with the increased incidence of type 2 diabetes. 
Startlingly, the rate of obesity development is not greatest in adults; rather, children and 
adolescence have experienced the greatest rate of obesity development. Nearly 17% of 
U.S. children are obese and that figure has tripled since 1980 (84, 141). Globally, nearly 
1.5 billion adults and over 40 million children are overweight or obese, as reported by the 
World Health Organization in 2008 (19). In the United States, over one-third of the adult 
population is obese (62). Additionally, approximately 190,000 Americans under the age 
of 20 have been diagnosed with type 2 diabetes and that number continues to increase. 
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Therefore, there is an urgent need for research in dietary contributions and modifications 
to halt the progression of, and lower the incidence of, type 2 diabetes worldwide.  
1.2 Diet impact on diabetes 
 In an effort to reduce the risk of developing type 2 diabetes, many dietary 
recommendations have been made. Dietary components, such as carbohydrates, proteins 
and fats, have all been adjusted in an effort to lower blood glucose levels. The 
components of the diet, especially the amounts and types of fat, are major contributors to 
obesity and diabetes. However, a major problem still remains: overconsumption of 
nutrients leads to the development of obesity and type 2 diabetes. Americans are 
practiced in over-nutrition, too many calories and too much of each nutrient, 
carbohydrate, protein and fat. An average American man requires approximately 2000 
calories a day to maintain normal weight and function (46). However, consuming over 
2000 calories is more common than not, leading to weight gain and obesity. Additionally, 
these dietary calculations have not been adjusted for changes in energy expenditure (18). 
Most Americans are not expending 2000 calories per day and therefore should be 
consuming less than 2000 calories (152).  
Dietary interventions have been employed throughout type 2 diabetes treatment 
history. In early diabetes research, the removal of carbohydrates from the diet was 
thought to help control blood glucose levels (87, 93, 133, 159). While this does tend to be 
effective for a brief time, the frank removal of a nutrient group is not sustainable. With 
glycemic index monitoring, different types of carbohydrates have been shown to affect 
blood glucose levels differently. On the basis of these observations, adjusting the diet to 
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incorporate more of the carbohydrates that do not adversely affect blood glucose levels 
has been promoted (159).  
In the low glycemic index diets, such as the Zone and South Beach diets, 
carbohydrates are ranked according to their capability to increase blood glucose levels on 
a scale of 1-100 with 100 being the glucose reference point (133, 159). Low glycemic 
carbohydrates are more slowly absorbed so as to minimize blood glucose spikes. A few 
examples of low glycemic foods are whole grains, fruits and legumes; however, some 
low glycemic foods such as candy bars with nuts are not healthy (133). Though these 
foods contain low glycemic loads, they may also contain more fat. Additionally, the 
major outcome of these diets is not necessarily lower blood glucose, but a weight 
reduction by removing excess calories from the diet (59).  
 The Atkins diet has exploited the differential energy utilizations of protein and fat 
for weight loss. The Atkins diet is a low carbohydrate, high protein, moderate fat diet that 
has been beneficial in promoting weight loss (1, 2, 107, 113, 145, 153). Dietary 
components have different energy content. While carbohydrates, in the form of glucose, 
are the preferred energy source of our bodies, more energy can be extracted from proteins 
and fats than from carbohydrates. However, this increase energy extraction comes at a 
price. More energy is required for the metabolism of proteins and fats than for 
carbohydrate metabolism. The Atkins diet prescribes an elimination of carbohydrates 
from the diet while increasing protein intake regardless of fat content (168). The 
elimination of carbohydrates removes the preferred and efficient fuel source from the 
body. Metabolism of proteins and fats essentially burns more energy and is much slower 
than carbohydrate metabolism thus resulting in rapid weight loss. However, this diet has 
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some drawbacks. Low carbohydrate/high protein diets like the Atkins diet require the 
adoption of special precautions because of increased risk of raising plasma cholesterol 
levels (8). Additionally, the body as a system cannot be maintained on this limited diet. 
Most often, protein and fat are over consumed and converted to fat, thereby increasing 
body mass and defeating the ability of the diet to control blood glucose levels.  
Diets such as the Atkins diet and the Mediterranean diet are utilized to lower 
blood glucose levels and body mass. The Mediterranean diet is a low fat, high fiber diet 
that has a low glycemic load and is rich in unsaturated fat. It promotes decreased insulin 
resistance and weight, both of which contribute to lower risk of developing type 2 
diabetes and cardiovascular disease (144). The Mediterranean diet gained popularity after 
several observational studies concluded that the incidences of diabetes and coronary heart 
disease are lowest in Mediterranean countries (103).  The Mediterranean diet is high in 
unsaturated fat, indicating that, in addition to the amount of fat consumed in the diet, the 
kind of fat consumed may be important.  
 A reoccurring theme throughout the literature is that the normal, healthy diet 
should principally contain unsaturated fats with low amounts of saturated fats and no 
trans fats (16, 17, 24, 34, 60, 67, 73, 76, 81, 82, 87, 104, 111, 124, 127, 135, 146, 151, 
156, 165, 177). The recommended decrease in fat intake is beneficial in treating both 
obesity and type 2 diabetes by promoting weight loss. On average, a 7% or greater 
reduction in weight while on a fat or calorie restricted diet has been shown to decrease 
overall body mass and reduce diabetic symptoms, such as insulin resistance (6). The 
dietary modifications suggested by both the American Diabetes Association and the 
World Health Organization are increased dietary fiber and decreased overall fat intake, 
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especially minimizing saturated and trans fat intake (122). The overconsumption of 
dietary fats is a major risk factor in developing obesity and obesity-related diseases such 
as type 2 diabetes.  
 The current dietary treatments for type 2 diabetes, including the Atkins, 
Mediterranean, and South Beach diets, have depended upon elimination of a nutrient 
group and focused on decreasing body mass to reduce blood glucose and halt the 
progression of type 2 diabetes. However, these high failure rates and short lifespan of 
these diets makes them poor permanent solutions for the treatment of type 2 diabetes. A 
more focused approach by closely examining the differential effects of fats in the diet 
might be more effective in minimizing type 2 diabetes and its physiological 
consequences.  
1.3 Dietary Fat 
Dietary fats can be classified as either saturated, unsaturated, or trans depending 
on the types, placement, and origination of carbon-carbon bonds in the fatty acids 
(Figure 1.3.1). In saturated fats, each carbon is fully saturated with hydrogen and 
therefore the carbons have only single bonds between them (92). Unsaturated fats have at 
least one double bond and are named by the placement of the double bond (63). Trans 
fats, which rarely occur in nature, are unsaturated fats where the carbon chains extend off 
of the opposite sides of the double bond. Trans fats, were developed as a butter 
alternative in response to population growth, widespread use of refrigeration, and 
decreased butter supply (112). All classes of fats can vary in chain length, and this 
variation in chain length also alters the metabolism of fats. Long fatty acids require 
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additional cleavage steps, decarboxylation, to convert each long fatty acid into acetyl 
groups that enter the Krebs cycle during metabolism (176). 
Many studies investigating the effects of dietary fat are not diet studies at all but 
instead are biochemical studies in cultured cell models (54, 111, 125, 142, 148, 151). 
Culturing cells in specific concentrations of dietary fat cannot hope to provide an 
accurate picture of how the body handles (metabolism and absorption) fat. These studies 
only tell us how the cells tolerate the concentration of fat in the culture media. The 
amount of fat added to the culture media may not be an accurate representation of the 
amount of fatty acid that is actually bathing the cells after absorption and metabolism of 
the fat.  
  This dissertation examines two dietary fats typically found in the American diet: 
stearic acid, a saturated fat, and oleic acid, a mono-unsaturated fat and their effects on 
blood glucose levels in a diabetic mouse model. The major flaw in the thought that the 
saturation of fat can predict the incidence of cardiovascular disease is that not all fats 
have been thoroughly investigated for their metabolic properties. Lumping a group of fats 
together based on the results given by one or two fats is not a valid venture. This 
dissertation examines the nutritional and metabolic differences between stearic acid, a 
saturated fat, and oleic acid, an unsaturated fat in diabetic and wild-type mice.  
Studies of saturated fats have concluded that saturated fats increase the risk for 
cardiovascular disease, increase plasma cholesterol levels, and promote insulin resistance 
(74, 86, 162). Studies of unsaturated fats have found that unsaturated fat decreases risk 
for cardiovascular disease and; decreases cholesterol levels only if included in a low fat 
diet regimen (9, 23, 71). However, insulin resistance and blood glucose levels are 
 
7 
unchanged if they are included in a high fat diet, typical of the American diet (98, 174). 
The lack of concrete mechanistic and long-term nutritional studies on the effects of 
individual fatty acids in the diets of healthy subjects fuels the good versus bad fat debate. 
This study investigated the differential effects of one saturated fat, stearic acid, and one 
unsaturated fat, oleic acid, on the progression of type 2 diabetes. 
1.3.1 Saturated fat  
Estimates of the total content of saturated fat in the typical American diet varies 
from as high as 25% to as low as 12% of the total calories coming from saturated fat (10, 
16, 21). In the third National Health and Nutrition examination Survey, the average 
saturated fat content in the diet was assessed at only 12% (5).  The current National 
Research Council recommendation for saturated fat consumption is 10% or less of the 
total daily caloric intake (76, 114, 177). The progressive elimination of dietary saturated 
fat has driven the commercial use of hydrogenation of unsaturated fats to provide an 
easier and more stable cooking alternative to butter.  
The lack of scientific and mechanistic understanding of the detrimental effects of 
saturated fat on plasma lipoprotein levels makes it possible that broad generalizations 
about this fat class are premature and unwarranted. Saturated fats have been labeled as 
‘bad fats’ because of their association with increasing overall plasma lipoprotein levels 
(21, 37, 47, 48, 110, 132, 134). Therefore, only saturated fats that deleteriously effect 
plasma cholesterol levels have been extensively studied. The most studied dietary 
saturated fat is palmitic acid. However, other saturated fats have beneficial effects on 
plasma cholesterol levels. One of the beneficial saturated fats is stearic acid (15, 140).  
 
8 
1.3.2 Stearic acid 
The U.S. Beef and Cattle Industry reports that beef is one of the dietary protein 
staples in the U.S., with over 25 billion pounds of beef consumed every year (47, 96, 
134). Stearic acid constitutes roughly 25% of the total saturated fat consumed by 
Americans and is found in highest abundance in red meat, coconut oil, and cocoa butter 
(40, 47). Although stearic acid is one of the major fats in the American diet, few studies 
have examined the effects of stearic acid on the progression of obesity and obesity related 
diseases such as type 2 diabetes or the effects of dietary stearic acid on blood glucose 
levels, insulin sensitivity or glucose tolerance. Since stearic acid has been categorically 
classified as one of the detrimental fats along with all other saturated fats, it is not 
included in most dietary studies even though it is a major fat in the American diet (119, 
171). This lack of research and the categorization of fats have left saturated fat relatively 
unexplored in terms of metabolic effects and therefore open to misinterpretation, 
especially in dietary recommendations for treatment of disease. 
Since the consumption of dietary saturated fat is linked with cardiovascular 
incidences, many studies have evaluated the effect of stearic acid on plasma lipoproteins. 
The majority of these studies have found that stearic acid is beneficial in lowering total 
LDL cholesterol levels, but HDL and total cholesterol levels are elevated (53, 75). A few 
studies have found that stearic acid does not alter the plasma cholesterol profile (37, 110). 
A few other studies show that stearic acid lowers total cholesterol as well as LDL levels 
(42, 158). These results are contradictory to the current thought that all saturated fats 
should be avoided due to the increased total plasma cholesterol effect some saturated fats 
have shown. Consequently, stearic acid is considered to be a neutral or inert fat unlike 
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most other saturated fats (21, 72, 75, 158). The neutral or beneficial effects of stearic acid 
on plasma cholesterol levels are an indicator that stearic acid is not like most saturated 
fats and may have additional beneficial effects that can be used to treat type 2 diabetes. 
Stearic acid could be used as a dietary treatment for type 2 diabetes without the concern 
of harmful cardiovascular effects since stearic acid has neutral effects on plasma 
lipoproteins. 
1.3.3 Unsaturated fat 
Another category of dietary fats is unsaturated fat. These fats have a least one 
double carbon-carbon bond in the chain. Unsaturated fats have been promoted as ‘good 
fats’ because they lower LDL and increase HDL levels when compared to the effects of 
saturated fats (27). They have usurped many saturated fats in the diet as a preventative 
measure against diabetes and cardiovascular disease because of these plasma lipoprotein 
effects.  
Though unsaturated fats are all promoted as healthy fats, there are inconsistencies 
and contradictions in this branch of fats as well. In diabetes research, mono-unsaturated 
omega-9 and the poly-unsaturated omega-6 fats have been reported to be both beneficial 
and detrimental for insulin resistance (3, 14, 113, 116).  
Some unsaturated fats are also linked to plaque formation, a similar observation 
as in saturated fats. Poly-unsaturated fats have also been shown to accumulate in arteries 
and form atherosclerotic plaques (60). Conversely, unsaturated fats called omega-3 fatty 
acids, found in cold-water fish such as salmon and herring, are positively associated with 
reductions in atherosclerotic plaque formations and reductions in plasma cholesterol. In 
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diabetes, these fats are linked to reversing insulin resistance. However, like many other 
fatty acids, the mechanism of action is unknown.  
It is interesting that in both classes of fats there are contradictions amongst the 
members of each class. Some saturated fats, like stearic acid have no negative effects on 
insulin or plasma lipoproteins, and some unsaturated fats, like the polyunsaturated fats, 
have no positive effects on insulin resistance or plasma lipoprotein levels.  
1.3.4 Oleic acid 
 One dietary recommendation prescribed to type 2 diabetics is the Mediterranean 
diet, a moderate fat diet (~20% kcal from fat) enriched in fruits, legumes and olive oil, 
which provides the major fat in the diet. The major fatty acid component of olive oil is 
oleic acid, the unsaturated fat that health professionals have recommended to be in the 
diet.  Oleic acid is a mono-unsaturated dietary fat that is, like stearic acid, 18-carbons in 
length with one double bond at the ninth carbon.  Oleic acid has been reported to 
decrease insulin resistance (16).  
Additionally, oleic acid has been shown to decrease total plasma cholesterol and 
low density lipoprotein (LDL) levels while increasing high density lipoprotein (HDL) 
levels (111). There has been no association between oleic acid and poor fatty acid 
absorption from the gut. The absorption of oleic acid is comparable to the absorption of 
palmitic acid, perhaps the most studied dietary fat (64). This positive effect on plasma 
lipoproteins has caused nutritionist and patient care specialists to recommend the use of 
oleic acid as a dietary mechanism to control or lower blood glucose levels.  
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1.4 Animal models of type 2 diabetes 
 The experimental limitations of human studies make appropriate animal models a 
valuable tool in identifying mechanisms of type 2 diabetes progression. Moreover, animal 
models are useful for developing and testing new treatments of human disease. An ideal 
model of type 2 diabetes is one in which the physiological aspects of human type 2 
diabetes can be easily and efficiently reproduced.   
 The db/db mouse model is an attractive model for type 2 diabetes because the 
human disease can be easily and efficiently reproduced in this mouse. Hummel et al (88) 
first described the db/db mouse in 1966 as a model for type 2 diabetes. In this mouse 
model, a leptin receptor defect results in a truncated form of the leptin receptor protein 
(88). This truncated leptin receptor results in a hyperphagic and obese mouse, similar to 
human type 2 diabetes, that decreases active receptor formation, decreases ligand 
binding, and decreases receptor activation (115). This truncated leptin receptor is also 
found in humans,  and though it is not the cause of the majority of diabetic cases, serves 
as an efficient, malleable model of human type 2 diabetes (61). 
Leptin is an adipocyte secreted protein that regulates satiety in the hypothalamus 
of the brain. After a meal, leptin is secreted from the adipocytes and feeds back onto the 
satiety pathway stopping the urge to eat. Without leptin, the negative feedback system is 
lost, and the animal eats insatiably and gains weight. 
Type 2 diabetes progresses quickly in the db/db mouse model. As early as ten 
days of age, db/db mice have increased insulin secretion and moderate hyperglycemia.  
Plasma insulin levels continue to increase for three months as beta cell mass increases in 
an attempt to compensate for the increased severity of hyperglycemia (61). A drop in 
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insulin to near normal levels may occur after three months of age as the beta cells begin 
to atrophy and die (61). Plasma glucose levels increase to over 400 mg/dl, a level that is 
maintained throughout the lifespan of the mouse leading to an abbreviated lifespan 
compared to the wild-type mouse (38).  
1.5 Statement of Research 
 Overconsumption of the diet is widespread and leads to obesity and type 2 
diabetes. High dietary fat is one of major contributors to obesity and type 2 diabetes. 
Some nutritional interventions have aimed at decreasing carbohydrate and fat content in 
the diet in an effort to lower body mass and blood glucose levels. However, the success 
rate and longevity of these diets are low. Previous nutritional studies have shown that 
saturated fat increases the risk for cardiovascular disease as well as type 2 diabetes and 
additionally have shown that low fat diets enriched in unsaturated fats, such as oleic acid, 
could improve insulin resistance, lower body mass and blood glucose levels. The current 
American Diabetes Association recommendations of a low fat diet containing mostly 
unsaturated fats and exclude most saturated and all trans fats. These past studies have 
done little to examine the effects of individual fatty acids on weight and blood glucose 
levels. 
The human diet is composed of a mixture of fats making it challenging to draw 
conclusions about the impact of any particular fatty acid on the progression of disease 
states such as diabetes.  Therefore, more studies are necessary to evaluate the effects of 
specific fatty acids, such as stearic and oleic acids, on diabetes and heart disease. Most of 
what is known about the functions of fatty acids is fragmented and biased by the 
assumptions made within the experimental investigations in which the fatty acids were 
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studied. This bias is particularly true for studies of the saturated fatty acids, most of 
which have been examined solely for their tendency to alter lipoprotein metabolism and 
to influence the concentrations of lipoproteins that carry cholesterol in blood. 
 Stearic acid is one of the three most common saturated fats in the diet, 
constituting roughly 25% of the total saturated fat consumed by Americans. It is found in 
highest abundance in red meat, coconut oil and cocoa butter (40, 47). Since stearic acid 
has been categorically classified as one of the detrimental fats, few studies have 
examined the specific effects of stearic acid on blood glucose levels or insulin sensitivity 
(55, 123). In cardiovascular research, stearic acid has no effect on plasma cholesterol 
levels (75). Consequently, stearic acid is considered to be a neutral or inert fat, unlike 
most other saturated fats (21, 72, 75, 158).  
 For this study, high fat diets were designed to mimic Western diets that typically 
contain at least 35% of their caloric value from fat; the experimental diets contained 40% 
of the total kilocalories from fat. For each experimental diet, the majority of the fat 
content was either in the form of stearic acid (85% of total fat) or oleic acid (67% of total 
fat). These diets were fed to db/db mice and wild-type mice for ten weeks.  
Aim 1: Determine if a high fat diet enriched in stearic acid slows the progression of 
type 2 diabetes in diabetic (db/db) mice. High fat diets enriched in saturated fat have 
been labeled as detrimental to overall health and allegedly linked to elevated incidence of 
cardiovascular events. However, the saturated fat stearic acid has no effect on plasma 
cholesterol levels unlike the saturated fat palmitic acid, which increases LDL cholesterol. 
If stearic acid has beneficial effects on type 2 diabetes, it could be included in the diet 
without detrimental cardiovascular effects.  
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Aim 2: Determine the appropriate dietary dose to get a beneficial effect of decreased 
blood glucose from stearic acid in db/db mice. A high-fat diet has clinical 
complications other than type 2 diabetes, such as cardiovascular disease and obesity. 
While the high fat diet enriched in stearic acid may have beneficial effects, it is unlikely 
that nutritionists and patient care specialists will recommend a high fat diet to patients. 
Additionally, the U.S. Department of Agriculture recommends a diet containing less than 
30% fat. Therefore, lowering the fat content in the diet to 17% of the total kilocalories 
from fat may be a more viable and attractive dietary intervention for the treatment of type 
2 diabetes.  I created and tested a moderate fat diet enriched in stearic acid in order to 
evaluate the if stearic acid in a moderate fat diet had the same beneficial effects on blood 
glucose levels as the high fat diet enriched in stearic acid.   
Aim 3: Determine if a high fat diet enriched in stearic acid will lower blood glucose 
levels in diabetic mice with prolonged and untreated hyperglycemia. In humans, 
diabetes is not treated until after clinical symptoms, such as hyperglycemia, have been 
present, sometimes for years; therefore, the ability to rescue the normal blood glucose 
phenotype by diet modification would be advantageous.   
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Figure 1.3.1: Typical Dietary Fat Models.  
A. Stearic acid is an eighteen carbon saturated fat that is most abundant in red meat and 
chocolate. B. Oleic acid is an eighteen carbon unsaturated fat found in olive oil. C. Trans 
fats can be long or short chained unsaturated fats where hydrogens bound to the carbons 
at the double bond extend from the same side of the double bond. Red spheres are 
oxygen. 
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Chapter 2: A High Fat Diet Enriched in Stearic Acid Slows the Progression of Type 
2 Diabetes in db/db Mice 
 
2.1 Introduction 
A diet high in fat contributes to the progression of type 2 diabetes (24, 137, 151). 
Most diabetic nutritional studies have focused on general classes of dietary fat, saturated 
versus unsaturated, but have left any differential effects of individual fatty acids 
relatively unexplored (135, 142, 151). Previous studies reported that low fat diets 
enriched in unsaturated fats have beneficial effects on insulin sensitivity and glucose 
tolerance, but diets enriched in saturated fats have detrimental effects on insulin 
sensitivity and glucose tolerance (50, 54, 171). In contrast, all high-fat diets, other than n-
3 fatty acids, reportedly led to insulin resistance (165). These data suggest that the effects 
of dietary fats on the progression of type 2 diabetes can be predicted simply from the 
degree of saturation of ingested fat.  
 In cardiovascular research, individual fats have been studied for their effects on 
cholesterol profile and progression of cardiovascular disease. Saturated fats have, in fact, 
been labeled as ‘bad fats’ because of their association with increasing overall cholesterol 
and LDL levels (21, 37, 47, 48, 110, 132, 134). Conversely, unsaturated fats have been 
promoted as ‘good fats’ because they lower LDL and increase HDL levels when 
compared to the effects of saturated fats. They have usurped many saturated fats in the 
diet as a preventative measure against diabetes and cardiovascular disease. In particular, 
oleic acid, an 18-carbon mono-unsaturated fatty acid, lowers LDL and raises HDL levels 
when compared to the saturated fats palmitic acid and myristic acid (16). In the Western 
diet, at least 35% of the calories are from fat. The American Heart Association 
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recommends no more than 30% of calories be from fat in the diet (108). Given that 
positive orosensory feedback of dietary fat consumption works against efforts to reduce 
fat consumption, identifying specific fats that are inert or even beneficial in terms of type 
2 diabetes and cardiovascular disease would offer promising alternatives for nutritional 
intervention (39).   
  Stearic acid is one of the three most common saturated fats in the diet, 
constituting roughly 25% of the total saturated fat consumed by Americans.  It is found in 
highest abundance in red meat, coconut oil and cocoa butter (40, 47). Since stearic acid 
has been categorically classified as one of the detrimental fats, few studies have 
examined the effects of stearic acid on blood glucose levels or insulin sensitivity (55, 
123). In cardiovascular research, stearic acid has no effect on plasma cholesterol levels 
(75). Consequently, stearic acid is considered to be a neutral or inert fat, unlike most 
other saturated fats (21, 72, 75, 158). In this study I hypothesize that the 18-carbon 
saturated fat, stearic acid, has beneficial effects on the progression of diabetes. 
For this study, high fat diets were designed to mimic Western diets; the diets 
contained 40% of the total kilocalories from fat. The majority of the fat content was 
either in the form of stearic acid (85% of total fat) or oleic acid (67% of total fat). These 
diets were fed to db/db mice and wild-type mice for ten weeks. Db/db mice fed a high fat 
diet enriched in stearic acid had lower blood glucose levels than db/db mice fed either the 
high fat diet enriched in oleic acid or the standard chow diet. These effects on glucose 
were independent of weight loss. Instead, the stearic acid diet was associated with 
reduced fat absorption and as a consequence metabolic switches from fat to protein and 
carbohydrates for calories and energy derivation. 
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2.2 Materials and Methods 
2.2.1 Animals 
 Initial cohorts of wild-type, age-matched, male C57BLKS/J (WT, n=105) and 
BKS.Cg-Dock7
m
 +/+ Lepr
db
/J (db/db, n=105) mice were purchased from The Jackson 
Laboratory (Bar Harbor, Maine) at four weeks of age.  Upon receipt they were acclimated 
for one week to baseline conditions of a 12-hr light/dark cycle at 25°C on an ad libitum 
diet of commercially available rodent chow diet (2018 Teklad Global 18% Protein 
Rodent Diet; Harlan Laboratories, Madison, Wisconsin). At five weeks of age, I weighed 
the mice, gave each an ear tag, drew blood for a baseline blood glucose measurement, 
and randomly assigned each mouse to a diet group (n=5 mice per group per genotype). 
The diets were the baseline chow diet and two experimental diets (40% kcal stearic acid 
diet Harlan Teklad TD.04096, 40% kcal oleic acid diet TD.09055). Mice were fed ad 
libitum for 10 weeks. Metabolic measurements were performed every two weeks through 
the duration of the study (Figure 2.2.1). About one year later a second cohort of mice 
(n=10 animals per diet per genotype) was treated identically and used to make additional 
metabolic and food consumption measurements. Weight, blood glucose and insulin 
tolerance measurements were made only at the start of the diet and at the endpoint in this 
cohort of animals. A rescue study was designed with aged WT (n=16) and db/db mice 
(n=16) in a third, and final cohort. These mice were purchased from The Jackson 
Laboratory at 5 weeks of age and fed chow diet until 10 weeks of age. The mice were 
then switched to 40% stearic diet (n=8 per genotype) or 40% oleic diet (n=8 per diet 
group) and fed ad libitum for 6 weeks. Blood glucose, insulin tolerance and weight were 
measured at the start of diet and after 6 weeks on diet. Animal care and housing were 
 
19 
conducted according to the NIH Guide for the Care and Use of Laboratory Animals. All 
experiments were approved by the Institutional Animal Care and Use Committee at the 
University of Kentucky. 
2.2.2 Diets 
Tables 2.1, and 2.2 display the nutritional value and composition of each diet 
used in this study. The stearic and oleic acid diets used in this study contained similar 
percentages of protein and carbohydrate whereas chow diet contained slightly more of 
total kcal from protein and 60% total kcal from carbohydrates. The fat content of each 
diet was unique.  The experimental diets were custom made by Harlan Teklad using a 
modified TD.03459 diet. A Harlan Teklad nutritionist calculated all dietary nutritional 
values. 
2.2.3 Food Consumption 
Study diet (200g) was placed into the food manger of each cage. The remaining 
food was measured and replaced every 48 hours. Food consumption was calculated from 
the starting food and remaining food weights. Caloric and fat intakes were calculated 
from food intake data and caloric and fat values of specific diet. In a second study, 
metabolic monitoring cages were used to measure food consumption from a hanging food 
cage over a two-day period. 
2.2.4 Glucose Measurements and Insulin Tolerance Test 
 Insulin tolerance tests (ITT) were performed in the first cohort of mice every two 
weeks on five mice per diet group per genotype. Mice were weighed and then fasted for 
four hours in a clean cage prior to testing. Fasting blood glucose was measured by tail 
 
20 
prick just prior to insulin injection and at the times indicated in “Results” using a 
commercially available glucometer and test strips (One Touch Ultra Glucose Monitoring 
Kit, Lifescan, Milpitas, California). Mice were injected (i.p.) with human insulin (0.2U/g) 
(Lilly, Indianapolis, Indiana).  
2.2.5 Insulin ELISA 
 Blood collected from fasted animals (4 hour fast) was allowed to clot for 20 
minutes in a vacutainer, and then centrifuged at 1500 X g for 10 minutes to isolate serum. 
Serum was then snap-frozen and stored at -80C until analyzed. Plasma insulin levels 
were measured using a commercially available mouse/rat insulin ELISA kit (Millipore, 
Billerica, MA) and reported in ng/mL.  
2.2.6 Body Composition 
 Body composition, including fat mass and lean mass, was determined using 
EchoMRI Quantitative Magnetic Resonance Body Composition Analyzer (Echo Medical 
Systems, Houston, Texas) on conscious mice (n=5 per diet per genotype).  Conscious 
mice were placed into the measuring tube and the tube placed into the EchoMRI 
machine. The EchoMRI uses the distinctions in NMR amplitude signals of various tissues 
to determine mass of muscle, fat and body fluids. 
2.2.7 Oxygen Consumption 
 Five mice per diet group per genotype were acclimated to the oxygen 
consumption chambers for 30 minutes prior to indirect calorimetry measurements. 
Metabolic rate was indirectly determined using weight, temperature and oxygen 
consumption. Conscious mice were weighed and placed in oxygen consumption 
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chambers. Room air was pumped into and out of the chambers and analyzed for oxygen 
and carbon dioxide content (mL/hr) using a CWE metabolic monitoring system and 
software (CWE, Allentown, Pennsylvania). Oxygen consumption was then computed 
from these measurements using the equation  ̇O2/weight (mL/g/hr) .   
 In a separate experiment, five db/db mice per diet group from the second cohort 
were acclimated in individual indirect calorimetry monitoring cages (TSE Labmaster 
Metabolism Research Platform, Midland, Michigan) with free access to experimental diet 
and water for three days during week ten of the diet study. After the acclimation period, 
complete metabolic data including activity level, food consumption, and water 
consumption were collected for 48 hours. From these measurements, activity levels 
during the mouse active period (18:00-06:00) were isolated to make resting metabolic 
rate calculations using the formula (160): 
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2.2.8 Immunohistochemistry 
 After all measurements were made, all animals in each group of mice (five mice 
per group per genotype; Figure 2.2.1) were anesthetized (3% isoflurane), euthanized by 
thoracotomy, and blood was collected by heart puncture.  Note, therefore, that an 
individual group was tested every two weeks of the study. Animal tissues were perfused 
with 10ml PBS (pH7.4) followed by perfusion fixation with 10mL of formalin (4% 
paraformaldehyde). Tissues were harvested, placed in formalin overnight at 4⁰C, and 
embedded in paraffin wax. Sections (5µm thickness) of each tissue were cut using a 
microtome and placed on PermaFrost glass slides. Sections were then de-paraffinized and 
used for immunohistochemistry. The following primary antibodies were used for insulin 
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and glucagon staining: guinea pig polyclonal anti-human insulin (1:50) and rabbit anti-
glucagon (1:250). The secondary antibodies were Cy3 donkey anti-guinea pig (1µg/ml) 
and Cy5 goat anti-rabbit (1µg/ml). All antibodies were purchased from Jackson Immuno 
Research (West Grove, Pennsylvania). Slides were processed for microscopy and images 
were taken at 20X magnification (Nikon Eclipse-Ti microscope, Melville, New York). 
The exposure time for anti-insulin was 300ms and for anti-glucagon was 3secs. Nikon 
NES Elements software was used to process images. Islet area was calculated by tracing 
the outline of each islet using the NES Elements software. For cell density calculations, 
cells with positive DAPI staining were counted as viable cells. Insulin-positive cells 
where counted as beta cells and glucagon-positive cells were counted as alpha cells. Cell 
density (total cell density, beta cell density, and alpha cell density) was calculated as total 
number of positive staining cells/area of the islet (m
2
). Alpha to beta cell ratio was 
calculated by total positive alpha cells/total positive beta cells per islet. Alpha cell 
migration was calculated by measuring the distance from the alpha cell to the outer edge 
of the islet and normalized to the length of the radius (using the geometric center of the 
islet section) passing through each cell.  
2.2.9 Gas Chromatography/Mass Spectrometry 
 Tissue, serum, and feces were collected post-mortem every two weeks during the 
study. Total fatty acids were extracted from 100mg of samples using Folch method. 
Extractions were then analyzed using GC/MS. Briefly, a 1 µl sample was injected into 
the gas chromatography system (model 6890GC G2579A system; Agilent, Palo Alto, 
California) equipped with a column (J&W DB5HT capillary columns, Agilent 
Technologies) and a flame ionization detector. An Agilent 5973 network mass selective 
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detector was used to identify target peaks of individual fatty acids. First, the corrected 
peak area of the FA of interest in the sample was calculated by multiplying by the ratio of 
peak area of the internal standard in standard set and the peak area of the internal 
standard in the sample and then multiplying by the ratio of the internal standard 
concentration in standard set and sample. Second, the concentration of the FA of interest 
was calculated by multiplying the corrected area of the interest peak by the ratio of the 
interest FA in the standard and in the sample. The two-step formula used is below.  
        (
             
           
)  (
              
            
) 
   denotes the peak area of the fatty acid of interest in the sample. The area of the peak is 
corrected for sample variation and      denotes the corrected peak area of the fatty acid of 
interest in the sample.               and             represent the area of the internal 
standard in the standard solution and in the sample. Next, the sample concentration was 
calculated. 
            (
              
           
) 
2.2.10 Data Analysis 
 Values are depicted as mean + standard error and considered significant if p < 
0.05. Data were statistically analyzed using two-way ANOVA with Bonferroni correction 
or one-way ANOVA with Dunnett’s post hoc test to identify which means differed using 
GraphPad Prism 5.01 for Windows (GraphPad Software, San Diego, California). NIS-
Elements 3.0 (Nikon Instruments, Elgin, Illinois) was used for finding islet area and cell 
counts. 
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2.3 Results 
2.3.1. A high fat diet enriched in stearic acid limits the progression of hyperglycemia 
in db/db mice. 
Fasting blood glucose levels were determined at the initiation of high fat diet 
feeding (week 0 baseline) and every two weeks during the ten week study for both WT 
and db/db mice. Data shown in Figure 2.3.1A are for baseline and measurements taken 
after 10 weeks on diet. For WT mice on chow or oleic acid diet the blood glucose levels 
did not change throughout the study. In contrast, WT mice fed stearic acid diet had 
significantly decreased fasting blood glucose beginning at two weeks on diet (not shown, 
Figure 2.3.1A). The baseline glucose levels for db/db mice were about two-fold higher 
than WT mice, as expected (38). Groups of db/db mice fed chow or oleic acid 
approximately doubled their blood glucose levels in ten weeks. In marked contrast, db/db 
mice fed stearic acid did not have an increase in blood glucose levels. 
 This experiment was repeated with a second cohort of animals. After ten weeks 
on diet, wild-type and db/db mice fed a high fat diet enriched in stearic acid had 
significantly lower blood glucose levels than the corresponding chow fed or oleic acid 
fed mice (Figure 2.3.1B). The db/db animal fed stearic acid also had blood glucose levels 
significantly lower than their baseline measurements. The db/db mice fed chow and a 
high fat diet enriched in oleic acid had significant increases in blood glucose from 
baseline measurements after 10weeks on diet.  
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2.3.2. Mice fed a high fat diet enriched in stearic acid have lower blood glucose after 
only two weeks on diet.  
After only 2 weeks on the high fat diet enriched in stearic acid, the db/db mice fed 
this diet had lower blood glucose levels than the db/db mice fed either oleic or chow diets 
(Figure 2.3.2). Decreases in blood glucose after diet intervention usually correspond to a 
decrease in body weight as well (45, 58, 101, 117, 129). This quick response to the diet 
has been reported in other diet interventions and may be explained by the gut flora 
adjusting to the new diet (32, 43, 78). The db/db mice on the stearic acid diet had an 
initial and abrupt decrease in blood glucose after 2 weeks on diet. However, the db/db 
mice fed stearic acid diet had slow and steady increases in blood glucose starting after 4 
weeks on diet.  
2.3.3. Body compositions of mice after 10 weeks on diets. 
 In diabetic models, low blood glucose levels are usually linked to decreases in 
weight (41, 59, 83). However, the first cohort of diabetic mice placed on high fat diets, 
gained weight over the ten week study (Figure 2.3.3A). The db/db mice fed oleic acid 
gained significantly more fat mass than the other db/db mice (Figure 2.3.3C) with no 
significant changes in lean mass (Figure 2.3.3B). WT mice fed chow diet gained lean 
mass from baseline (Figure 2.3.3B) while those fed oleic diet gained fat mass from 
baseline (Figure 2.3.3C). Importantly, db/db mice fed stearic acid also gained weight 
over the 10 week study; therefore, their decreased blood glucose levels were not caused 
by weight loss. Recall that db/db mice fed the stearic acid diet had lower glucose levels 
than mice fed the oleic acid diet. These mice also maintained a stable weight over the 
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course of the experiment (Figure 2.3.3D), confirming that the effects of stearic acid on 
blood glucose levels are not dependent on weight loss or gain. 
2.3.4. A high fat diet enriched in stearic acid does not promote weight loss in db/db 
mice. 
Normal diet interventions in diabetic models typically use weight loss as a guide 
of diet performance. Large weight loss usually corresponds to a decrease in blood glucose 
levels and an overall improvement in health. Interestingly, in this diet study, the db/db 
mice that were fed a high fat diet enriched in oleic acid, an unsaturated fat, gained a 
significant amount of weight over the course of the diet study as did the db/db mice fed 
chow diet (Figure 2.3.4). The db/db mice fed the oleic acid diet gained a significant 
amount of weight from baseline (start of the diet). Even more interestingly, the db/db 
mice fed a high fat diet enriched in stearic acid, a saturated fat, did not gain a significant 
amount of weight over the course of the ten week diet study. These mice did weigh more 
than their wild-type counterparts indicating that they were still obese mice; however, 
unlike the db/db mice fed high fat diet enriched in oleic acid, the stearic acid fed mice 
were able to maintain a consistent weight for the duration of the study, with one 
exception: the db/db mice fed stearic acid did experience an initial weight loss after 4 
weeks on diet, but all mice regained the lost weight and more, becoming 
indistinguishable in weight from mice fed chow and oleic acid diets.   
2.3.5. Diabetic mice fed a high fat diet enriched in stearic acid had lower metabolic 
rates than chow fed diabetic mice. 
Increases in resting metabolic rate or in activity could result in lower blood 
glucose levels without concomitant weight loss. To assess these alternate explanations, I 
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used indirect calorimetry cages and calculated resting metabolic rate from the oxygen 
consumption and activity measurements of db/db mice after 10 weeks. Db/db mice fed 
oleic acid diet had resting metabolic rates no different than chow fed db/db mice and 
significantly higher than stearic acid fed db/db mice (Figure 2.3.5). In fact, the db/db 
mice fed stearic acid had lower resting metabolic rate than both the oleic and chow fed 
db/db groups. That is, stearic acid did not increase resting metabolic rate in db/db mice, 
but instead lowered the resting metabolic rate of these mice. Therefore, stearic acid did 
not affect the blood glucose levels of these mice by increasing the metabolic rate. 
2.3.6. Stearic acid fed db/db mice had no differences in activity level compared to 
chow fed animals.  
 Since db/db mice fed stearic acid had lower metabolic rates than the db/db mice 
fed chow and oleic acid diets, I examined the activity level, one of the variables in 
metabolic rate, from the stearic acid fed mice while in the calorimetric cages. I found that 
the activity levels of db/db mice fed the stearic acid diet did not differ from those of the 
db/db mice fed the chow and oleic acid diets (Figure 2.3.6). Therefore, decreased activity 
was not the explanation for the lower metabolic rate seen in the db/db mice fed a high fat 
diet enriched in stearic acid.   
2.3.7. Mice fed a high fat diet enriched in stearic acid consumed less food than chow 
or oleic acid diet groups. 
Another factor that could affect blood glucose is reduction in food consumption 
compared to baseline or across dietary groups. Interestingly, db/db mice fed the high fat 
diet enriched in stearic acid consumed less food than db/db mice fed either chow or oleic 
acid-enriched diet (Figure 2.3.7). Although the db/db mice fed the stearic acid diet 
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consumed less food, the amount consumed was sufficient to maintain their weight 
equivalent to wild-type mice. These data suggest that even though calories consumed 
were sufficient to maintain a normal weight, db/db mice must have consumed less fat. 
2.3.8. db/db mice absorb dietary stearic acid poorly. 
Another means by which stearic acid might contribute to reduced fat load is if 
stearic acid were poorly absorbed from the gut as compared to other fats. I therefore 
examined the fatty acids excreted in the feces. Db/db mice fed the stearic acid-enriched 
diet excreted substantial amounts of stearic acid in the feces while mice fed oleic acid did 
not show increased excretion of oleic or stearic acid in the feces (Figure 2.3.8). Unlike 
oleic acid, the stearic acid was poorly absorbed by the mice. These findings argue that 
mice fed the stearic acid diet not only ingested fewer calories but also obtained a lower 
percentage of calories from fat than mice fed the other diets.  
2.3.9. A high fat diet enriched in stearic acid does not cause an increase in fat 
accumulation in the liver. 
Given that less fat was absorbed from the stearic acid diet, then these mice should 
show less accumulation of fatty acid in the liver, a major site of fatty acid accumulation 
in diabetic mice. The db/db mice, regardless of diet, had greater accumulation of fatty 
acid in the liver than wild-type mice (p<0.05, n=5 per diet group per genotype), as has 
been previously documented for db/db mice (147). However significant additional fatty 
acid accumulation in the liver over the 10 week study only occurred in db/db mice fed 
oleic acid, and only oleic acid, not stearic acid, increased in the livers of these mice 
(Figure 3.3.9). A diet enriched in stearic acid did not contribute to an excess 
accumulation of fat in the liver which is consistent with the observation that these mice 
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had lower absorption of dietary stearic acid from the gut than db/db mice fed either the 
chow or oleic diets.   
2.3.10. A high fat diet enriched in stearic acid did not diminish insulin 
responsiveness. 
A reduction of fat absorption and lower blood glucose may also indicate improved 
insulin tolerance. Diets rich in unsaturated fat, especially oleic acid, and low fat diets 
decrease insulin resistance in db/db mice (16, 136, 154, 163, 170). After 10 weeks on 
diet, WT mice had no change from baseline in insulin response (Figure 2.3.10A and C). 
Though db/db mice fed stearic acid diet seemed to have insulin tolerance similar to 
baseline (Figure 2.3.10B), when plotted as a percent of fasting blood glucose 
measurement, the effect was not maintained (Figure 2.3.10D). Similarly, no change in 
insulin tolerance was observed in mice fed the chow and the oleic acid diets.  
2.3.11. A high fat diet enriched in stearic acid did not alter plasma insulin content. 
Since db/db mice fed a high fat diet enriched in stearic acid did not have 
decreased insulin sensitivity, I hypothesized that the pancreatic islet organization in these 
animals would be normal. Moreover, these animals should be spared from any pancreatic 
apoptosis that has been associated with the progression of type 2 diabetes (34, 35, 57, 
127). As predicted, I observed no differences in plasma insulin levels in any of the diet 
groups after ten weeks on diet (Figure 2.3.11). These findings argue that pancreatic islets 
in the mice fed stearic acid diet would be spared the apoptotic loss of beta cells and the 
subsequent disorganization that normally accompanies the progression of type 2 diabetes 
in this model (34, 57, 127).  
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2.3.12. A high fat diet enriched in stearic acid protected the pancreatic islets of 
db/db mice from disorganization. 
Pancreatic islets of WT mice appeared normal after 10 weeks on high fat diets 
(Figure 2.3.12 A, C, E, G). In contrast, db/db mice fed the chow and oleic acid diets for 
ten weeks had evidence of islet disorganization (Figure 2.3.12 B, D, F, H). Specifically, 
the alpha cells, which normally lie in the outer ring of the islet, invaded the inner mass of 
the islets. Additionally, the islets’ cores had more areas devoid of insulin and/or glucagon 
staining, consistent with the beginnings of β cell loss that is characteristic of advanced 
type 2 diabetes (99, 118). In contrast, db/db mice fed stearic acid diet for ten weeks had 
normal islet organization. Beta cell to alpha cell ratio was maintained in the db/db mice 
fed stearic acid but was disrupted in the db/db mice fed chow and oleic acid diets (Figure 
2.3.12 C).  
2.4. Discussion 
Our results indicate that mice fed a high fat diet enriched in stearic acid had lower 
blood glucose levels and normal appearing pancreatic islets compared to mice fed other 
diets. These effects were not dependent on weight loss or altered resting metabolic rate. 
Instead, the beneficial effects of stearic acid were associated with poor absorption of 
stearic acid from the gut. That these mice were able to increase or maintain body weight 
argues that the mice must have increased utilization of the other energy sources in the 
diet, carbohydrates and proteins. More broadly, the benefits of a diet in which the fat 
content is primarily stearic acid, a saturated fat, argue that expecting all saturated fats in 
the diet to have the same effects is not justified. Similarly, the detrimental effects of the 
oleic acid-enriched diet which I have documented argue that overconsumption of this 
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unsaturated fat, whose consumption has been promoted due to benefits for cardiac health, 
elevates risk of diabetes.  
 Several animal studies have shown that stearic acid has lower absorption from the 
gut than other fats (25, 91, 134), yet another study found no differences (20). The 
resolution of these conflicting data is the mode of fat delivery; only when liquid fat diets 
were delivered orally or by infusion was absorption of stearic acid comparable to other 
fats. I used stearic acid in its natural solid fat form in our diet. To maximize the 
translatability of this study, I chose a normal oral delivery route involving stearic acid-
enriched food pellets.  
 Human dietary studies with stearic acid have resulted in a wide range of 
absorption values. These discrepancies may be due to the amount and type of stearic acid 
in the diet, the length of the study, and the method used to detect absorption. In a recent 
study, Baer and colleagues (10) reported lower absorption of stearic acid as compared to 
palmitic acid and myristic acid by examination of fecal fatty acid content after feeding 
diet for two weeks. This study, similar to our study, included mixed fat diets with higher 
percentages of experimental fats and followed male participants over time to allow for 
adjustments to the diet. Conversely, Bonanome and Grundy (22) evaluated fatty acid 
incorporation into chylomicrons after one fatty  meal and found no difference in stearic 
acid incorporation into chylomicrons as compared to palmitic acid. This snapshot, while 
useful for determining effects of stearic acid in plasma lipid profile, does not offer insight 
into long-term weight maintenance and glucose homeostasis. My study offers a new 
perspective on dietary fat intake and the progression of diabetes by using a long-term diet 
scheme and additional measures of metabolic parameters. 
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 In this study, I found that mice fed a diet enriched in stearic acid had decreased 
food consumption. This decrease in food consumed may be due to the poor palatability of 
stearic acid in mice. Most fat in food is in the form of triglycerides. However in this diet 
study, we enriched the stearic acid diet with pure stearic acid, a free fatty acid. Fat 
palatability is linked to the ability of the fatty acid to activate fatty acid receptors, CD36 
and GPR120, on tongue (65, 68, 102) . Saturated fats have a low affinity for these fatty 
acid receptors therefore the food enriched in saturated fat would be unpalatable to the 
mice (85, 130). Previous studies have shown that the palatability of fatty acids differs, 
and mice prefer unsaturated long-chain fatty acids over saturated long-chain fatty acids 
(155, 175). Additionally, high concentrations of fatty acids do not occur naturally in any 
food; therefore mice never experience them. This is not to say the same system is not 
present it humans. However, humans are exposed to higher concentrations of fatty acids 
in foods than mice and may utilize more than tongue fatty acid receptors to determine 
palatability. Therefore, a high fat diet enriched in stearic acid, though causes a decrease 
in food consumption in mice, may not have the same orosensory effects in humans. 
 The ability of the stearic acid-enriched diet to slow, and even reverse, diabetic 
symptoms is similar to some more extreme diets. Fat and caloric restriction diets have 
been reported to lower blood glucose levels and improve insulin response in humans with 
type 2 diabetes. These interventions have worked by lowering the overall caloric content 
and glycemic load of the diet (49, 73, 76, 81-83, 94, 116, 126, 131, 149, 156, 161, 172). 
This similarity in outcomes lends additional support to the conclusion, driven by my 
evidence of poor absorption of stearic acid, that the stearic acid-enriched diet was 
effective for the same reason: shifting caloric utilization away from fats to carbohydrates 
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and proteins. However, the stearic acid diet achieved the same blood glucose lowering 
effect without having to restrict calories available to the mice. Neither did it force the 
mice to lose weight, a property unlike dietary modifications currently used for treating 
type 2 diabetes consists (3, 12). My data argue that weight loss is not the exclusive key to 
blood glucose management, but that a nutrient shift from fat to carbohydrates and 
proteins in the diet slows the progression of type 2 diabetes in the absence of weight loss. 
 As the data have demonstrated, the existing generalizations about saturated and 
unsaturated fats in the diet are not appropriate. I found that the effects of stearic acid 
greatly differ from those palmitic acid and myristic acid, more widely studied saturated 
fats. Consumption of a diet rich in stearic acid slowed the progression of type 2 diabetes. 
Conversely, consumption of palmitic acid and myristic acid has been shown to impair 
insulin sensitivity (139, 150). Similar differences among saturated fats are found in 
studies of cardiovascular disease. Palmitic acid, the most abundant saturated fatty acid  in 
the diet, detrimentally increases total plasma cholesterol levels (166), but myristic acid, a 
less common dietary saturated fat, beneficially raises HDL cholesterol (55, 121). Stearic 
acid is dissimilar from both of these saturated fats; it does not alter plasma cholesterol 
levels (21, 37, 91, 110).  
 Generalizations about unsaturated fats may also be inappropriate. Unsaturated fats 
have been promoted in the diet to replace saturated fats. However, if direct substitution is 
not accompanied by a reduction in overall fat intake, the overconsumption of these 
‘good’ fats may contribute to obesity and type 2 diabetes. I found that a high fat diet that 
consists mainly of oleic acid was not beneficial for lowering elevated blood glucose 
levels or decreasing weight in the obese mice. In fact, this mono-unsaturated fat enriched 
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diet accelerated the progression of diabetic symptoms in db/db mice. Our data argue that 
although unsaturated fats have benefits for cardiovascular health, their overconsumption 
may increase risk for type 2 diabetes. 
In a diabetic mouse model, a high fat diet enriched in stearic acid prevented an 
increase in blood glucose and maintained pancreatic islet organization independent of 
weight loss. These effects were associated with poor stearic acid absorption. Overall our 
data suggest that the benefits conferred from the stearic acid may have resulted in 
enhanced metabolic utilization of dietary carbohydrates and proteins instead of fat. 
Additionally, our data suggest that current dietary stands and generalizations about fat 
may be inappropriate and even detrimental in treating type 2 diabetes.   
  
 
35 
Table 2.1: Dietary Compositions 
 
Catalog Number Protein Carbohydrate Fat 
Chow TD. 2918 18.80 53.80 17.0 
40% kcal Stearic Acid TD. 04096 17.80 42.20 40.0 
40% kcal Oleic Acid TD. 09088 17.50 41.50 41.0 
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Table 2.2: 40% Diet Fat Composition 
 
 
  
 
Diet Chow Stearic Acid Oleic Acid 
% kcal from Fat 17.00 40.00 41.00 
 
% Stearic acid in fat 2.60 86.00 2.00 
% Oleic acid in fat 22.50 <1.00 64.00 
% Other Essential Fatty Acids 74.90 13.00 34.00 
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Figure 2.2.1: Experimental design for 40% high fat diet study. A total of 190 mice, 
95 wild-type mice and 95 diabetic (db/db) mice were used in these experiments. Mice 
were acclimated one week prior to the start of experimental diets and measurements. 
After the acclimation, five mice per genotype were measured for baseline (before diet 
initiation) control measurements and then euthanized for tissue processing. The 
remaining mice were assigned a diet group. Thirty mice of each genotype were assigned 
to the chow group, 30 were placed in the high fat diet enriched in stearic acid group, and 
the remaining 30 mice were placed in the high fat diet enriched in oleic acid diet group. 
After starting the diet, five mice per diet group per genotype were used for measurements 
and then euthanized for tissue collection every two weeks for the duration of the study 
with the final group euthanized at 24 weeks on diet. 
  
 
39 
 
 
Figure 2.3.1: The high fat diet enriched in stearic acid diet prevents an increase in 
fasting blood glucose in db/db mice. Five-week-old WT and db/db male mice were fed 
chow, stearic acid diet or oleic acid diet for 10 weeks.  Fasting blood glucose 
measurements were taken, using commercially available glucometer and tail prick 
methods. A: Fasting blood glucose levels of mice at baseline (0 weeks on diet) and after 
10 weeks on diet. * p<0.05, *** p<0.001. n = 5 mice per group per genotype. B: Fasting 
blood glucose levels of mice at baseline and after 10 weeks on diet, second cohort of 
mice. * p<0.05, ** p<0.01, *** p<0.001. n=5 mice per group per genotype. 
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Figure 2.3.2: db/db mice fed a high fat diet enriched in stearic acid had blood 
glucose levels similar to WT mice after 2 weeks on diet. db/db mice fed a high fat diet 
enriched in stearic acid had lower blood glucose after 2 weeks of diet administration (red 
tracing) than the db/db mice fed a high fat diet enriched in oleic acid and normal chow 
diet. Stearic acid fed db/db mice had blood glucose levels only slightly higher than any of 
the WT mice. N=5 mice per diet group per time point.  
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Figure 2.3.3: db/db mice fed a high fat diet enriched in stearic acid do not lose 
weight.  Weight, lean mass, and fat mass were measured using EchoMRI for all mice in 
the study after ten weeks on diet. A: WT and db/db body mass. db/db 10 week Oleic Acid 
significantly greater than all other diet groups. B: WT and db/db lean mass. C: WT and 
db/db fat mass. D: WT and db/db weight after 10 weeks on diet, second cohort of 
animals. ** p< 0.01, *** p<0.001 n= 5 mice per group per genotype.  
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Figure 2.3.4: A diet enriched in stearic acid promoted an early weight loss that was 
recovered by end of study. Db/db mice fed a high fat diet enriched in stearic acid had an 
initial decline in weight after 2 weeks on diet. After 4 weeks on diet, the mice gained 
weight and were no different in weight than their oleic acid or chow fed counterparts by 
the end of the ten week study. n=5 mice per diet group per time point.  
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Figure 2.3.5: db/db mice on the high fat diet enriched in stearic acid have lower 
metabolic rates. Resting metabolic rate was calculated from activity level and oxygen 
consumption measurements in metabolic monitoring cages. Db/db mice on stearic acid 
diet had significantly lower resting metabolic rate than db/db mice on chow and oleic 
acid diets after 10 weeks on diet. * p<0.05, ** p<0.01, *** p<0.001. n=2 mice in chow 
and oleic acid groups, n=5 mice in stearic acid group.  
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Figure 2.3.6: Stearic acid fed db/db mice showed no difference in activity level as 
compared to other diet groups. Activity data from calorimetry cages show no 
differences between diet groups. 
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Figure 2.3.7: db/db mice fed a high fat diet enriched in stearic acid consumed less 
food.  Wild-type mice had no significant difference in food consumption over the course 
of the diet study. Db/db mice fed a high fat diet enriched in stearic acid consumed 
significantly less food over the course of the ten week diet study as compared to chow or 
oleic acid fed animals. *** p<0.001, n=5 mice per group per genotype.  
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Figure 2.3.8: Dietary stearic acid causes an increase in fecal stearic acid excretion.  
Both WT and db/db mice fed a high fat diet enriched in stearic acid had increases in fecal 
excretion of stearic acid. Feces were collected from the mouse cages. Only the major 
dietary fatty acids are shown. Fecal fatty acid excretion at 10 weeks on diet from both 
WT and db/db mice in all three diet groups. ** p<0.01 stearic acid compared to all other 
diet groups within genotype. 
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Figure 2.3.9: A high fat diet enriched in stearic acid does not cause accumulation of 
stearic acid in the liver.  Fatty acid amounts in liver determined by GC/MS of livers 
from WT (A) and db/db mice (B). Note difference in ordinate scale in panel A and B. * 
p< 0.05 for comparison to baseline, n = 5 mice.  
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Figure 2.3.10: A stearic acid diet does not alter insulin sensitivity from baseline in 
db/db mice. Insulin tolerance test was performed on WT (A) and db/db (B) mice. Open 
triangle represents baseline; filled circle represents chow diet; open square represents 
stearic acid diet; filled triangle represents oleic acid diet. * p < 0.05 db/db mice time 0 
stearic vs. time 0 baseline, chow, and oleic diet; n=5 mice. C: WT mice percent fasting 
blood glucose. D: db/db mice percent fasting blood glucose levels.  
  
 
49 
 
Figure 2.3.11: Dietary stearic acid did not alter plasma insulin concentrations. 
Plasma insulin concentrations were unchanged from baseline in both WT and db/db mice 
fed the experimental diets. Though the db/db mice fed the 40% high fat diet enriched in 
stearic acid tended to have elevated plasma insulin compared to mice fed chow or oleic 
acid diets, the trend was not significant.   
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Figure 2.3.12: Stearic acid enriched diet preserves pancreatic islet organization. 
Representative images of WT and db/db pancreatic islets before and after diet 
intervention. Baseline (A and B), 10 week chow diet (C and D), 10 week stearic acid diet 
(E and F), and 10 week oleic acid diet (G and H).  Scale bar is 100µm.  
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Figure 2.3.13: A diet enriched in stearic acid preserves pancreatic islet area, total 
cell density, beta cell density, alpha cell density, and maintains beta cell mass. WT 
and db/db quantifications of pancreatic islet histology. Total islet area (A). Total cell 
density in islets (B). Beta cell density (C). Alpha cell density (D). Alpha cell to beta cell 
ratio in islets (E). Location of alpha cells in islet as measured by percent of the islet 
radius (F). *p<0.5, ** p<0.01, *** p<0.001. 
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Chapter 3: Stearic acid effects on the progression of type 2 diabetes in a moderate 
fat diet in the diabetic mouse model. 
3.1 Introduction 
High fat diets are linked to diseases such as cardiovascular disease and type 2 
diabetes; and, lowering the fat content of the diet offers beneficial results in slowing 
disease progression. Most Western diets contain at least 36% fat; however, the USDA 
currently recommends dietary fat content to be much lower, about 20% of the daily 
intake. Therefore, a moderate fat diet (17% kcal) may be a viable and attractive dietary 
option for the treatment of type 2 diabetes and more closely align with the current USDA 
and AHA recommendations than the 40% high fat diets. Therefore, decreasing the overall 
fat content in the diet will be more fitting to these current dietary guidelines.  
Encouraged by the positive results from the 40% kcal stearic acid enriched high 
fat diet study, I hypothesized that a moderate fat diet (17% kcal from fat) enriched in 
stearic acid may offer the same protection against the progression of type 2 diabetes 
while more closely aligning with the current dietary recommendations. Wild-type and 
diabetic mice were fed moderate fat diets for ten weeks and were assessed for progression 
of type 2 diabetes during the study.  
 Diabetic mice fed a moderate fat diet (17% fat) enriched in stearic acid were not 
protected from the progression of type 2 diabetes; however, the db/db mice fed the stearic 
acid enriched diet had blood glucose levels that were lower than the db/db mice fed the 
chow diet. Interestingly, all mice, both wild-type and db/db, had increased accumulation 
of oleic acid in the liver regardless of experimental diet.  
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3.2. Methods and Materials 
3.2.1 Animals 
 Age-matched, male C57BLKS/J (WT, n=105) and BKS.Cg-Dock7
m
 +/+ Lepr
db
/J 
(db/db, n=105) mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) 
at four- five weeks of age. All mice were allowed to acclimate for one week and fed ad 
libitum a commercially available rodent chow diet (Teklad Global 18% Protein Rodent 
Diet TD.2018) obtained from Harlan Laboratories (Madison, Wisconsin). Mice were kept 
on a 12-hr light/dark cycle at 25°C throughout the study. At five weeks of age, all mice 
were weighed, ear tagged, and randomly assigned to a study group. The three study 
groups were fed different diets: chow diet or one of two experimental diets (17% kcal 
stearic acid diet, Harlan Teklad TD.03459, 17% kcal oleic acid diet TD.09315). All mice 
were maintained one of these diets ad libitum for 10 weeks. Every two weeks for the 
duration of the study, metabolic measurements were performed using five mice per diet 
group per genotype. Weight, blood glucose and insulin tolerance measurements were 
taken at the start of the diet and at the endpoint in this cohort of animals. Figure 3.2.1 
shows the experimental design for this study. Animal care and housing conducted 
according to the NIH Guide for the Care and Use of Laboratory Animals. All 
experiments were approved by Institutional Animal Care and Use Committee at the 
University of Kentucky Animal Housing Facility and overseen by University of 
Kentucky veterinarians. 
3.2.2 Diets 
 Table 3.2.1 and Table 3.2.2 list the nutritional value and composition of each diet 
used in this study. The stearic and oleic acid diets used in this study contained similar 
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percentages of protein and carbohydrate whereas chow diet contained slightly more of 
total kcal from protein and 60% total kcal from carbohydrates. The fat content of each 
diet was unique. The experimental diets were custom made by Harlan Teklad using a 
modified TD.03459 diet. A Harlan Teklad nutritionist calculated all dietary nutritional 
values. 
3.2.3 Glucose Measurements and Insulin Tolerance Test 
 Insulin tolerance tests were performed every two weeks during the study on five 
mice per diet group per genotype. Mice were weighed and then fasted for four hours in a 
clean cage prior to testing. Fasting blood glucose was measured by tail prick with a 
commercially available glucometer and test strips (One Touch Ultra Glucose Monitoring 
Kit, Lifescan, Milpitas, California). Mice were injected (i.p.) with insulin (2mU/g) and 
blood glucose was measured (mg/dl) 0, 5, 10, 30, 60, 90 and 120 minutes after insulin 
injection. If blood glucose fell below 20mg/dL, mice were rescued with 200uL of 20% 
glucose solution (i.p.) and excluded from the ITT experiment. Blood glucose 
measurements were normalized to baseline measurements, and both sets of data plotted 
over time.  
3.2.4 Insulin ELISA 
 Every two weeks, collected blood from fasted animals (4 hour fast) was allowed 
to clot for 20 minutes in a vacutainer and centrifuged at 1500 X g for 10 minutes to 
isolate serum. Serum was then snap-frozen and stored at -80⁰C until analyzed. Plasma 
insulin levels were measured using a commercially available mouse/rat insulin ELISA 
(Millipore, Billerica, Massachusetts) and reported in ng/mL.  
 
56 
3.2.5 Body Composition 
 Every two weeks during the study, mouse body composition, including fat mass 
and lean mass, was determined using EchoMRI Quantitative Magnetic Resonance Body 
Composition Analyzer (Echo Medical Systems, Houston, Texas) on conscious mice (n=5 
per diet per genotype).  Conscious mice were placed into the measuring tube and the tube 
placed into the EchoMRI machine. The EchoMRI uses the distinctions in NMR 
amplitude signals of various tissues to determine mass of muscle, fat and body fluids. 
3.2.6 Oxygen Consumption 
 Every two weeks during the study, five mice per diet group per genotype were 
placed in oxygen consumption chambers for indirect calorimetry measurement. 
Metabolic rate was indirectly determined using weight, temperature and oxygen 
consumption. Conscious mice were weighed and placed in oxygen consumption 
chambers. Room air was pumped into and out of the chambers and analyzed for oxygen 
and carbon dioxide content (mL/hr) using a CWE metabolic monitoring system and 
software (CWE, Allentown, Pennsylvania). Oxygen consumption was then computed 
from these measurements using the equation VO2/weight (mL/g/hr).  
3.2.7 Gas Chromatography/Mass Spectrometry 
 Tissue, serum, and feces were collected post-mortem every two weeks during 
study. Total fatty acids were extracted from 100mg of samples using Folch method. 
Extractions were then analyzed using GC/MS. Briefly, a 1 µl sample was injected into 
the gas chromatography system (model 6890GC G2579A system; Agilent, Palo Alto, 
California) equipped with a column (J&W DB5HT capillary columns, Agilent 
Technologies) and a flame ionization detector. An Agilent 5973 network mass selective 
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detector was used to identify target peaks of individual fatty acids. First, the corrected 
peak area of the FA of interest in the sample was calculated by multiplying by the ratio of 
peak area of the internal standard in standard set and the peak area of the internal 
standard in the sample and then multiplying by the ratio of the internal standard 
concentration in standard set and sample. Second, the concentration of the FA of interest 
was calculated by multiplying the corrected area of the interest peak by the ratio of the 
interest FA in the standard and in the sample. The two-step formula used is below.  
        (
             
           
)  (
              
            
) 
   denotes the peak area of the fatty acid of interest in the sample. The area of the peak is 
corrected for sample variation and      denotes the corrected peak area of the fatty acid of 
interest in the sample.               and             represent the area of the internal 
standard in the standard solution and in the sample. Next, the sample concentration was 
calculated. 
            (
              
           
) 
3.2.8 Data Analysis  
 Values are depicted as mean + standard error and considered significant if p < 
0.05. Data were statistically analyzed using two-way ANOVA with Bonferroni correction 
or one-way ANOVA with Dunnett comparison posttest when appropriate using GraphPad 
Prism 5.01 for Windows (GraphPad Software, San Diego, California). NIS-Elements 3.0 
(Nikon Instruments, Elgin, Illinois) was used for islet area and staining analysis. 
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3.3 Results 
3.3.1 After 10 weeks on moderate fat diet, db/db mice fed stearic acid had blood 
glucose levels lower than chow fed mice. 
Fasting blood glucose levels were determined at the beginning of the moderate fat 
study (Baseline) and every two weeks during the ten week study for both WT and db/db 
mice (two week data was not collected due to fire alarm and mandatory evacuation of the 
building). These data shown in Figure 3.3.1 are for baseline and measurements taken 
after 10 weeks on diet. For WT mice on chow, stearic acid, or oleic acid diet the blood 
glucose levels did not change throughout the study. The baseline glucose levels for db/db 
mice were about 1.5-fold higher than WT mice, as expected (38). Db/db mice fed chow 
and oleic acid diets approximately doubled their blood glucose levels in ten weeks. In 
contrast, db/db mice fed stearic acid had increased blood glucose levels over baseline, but 
the level at ten weeks was significantly lower than the chow fed db/db mice.  
3.3.2 Weight and body composition remained unchanged after moderate fat feeding. 
In diabetic models, lowered blood glucose levels are usually linked to decreases 
in weight (41, 59, 83). The db/db mice placed on moderate fat diets had no changes in 
weight after ten weeks on diet (Figure 3.3.2A). The db/db mice had no changes in fat 
mass vs. baseline after ten weeks on diet (Figure 3.3.2B). Interestingly, the db/db mice 
fed stearic acid had decreased lean mass from baseline and also compared to chow and 
oleic acid fed db/db mice (Figure 3.3.2C). WT mice gained weight over the course of the 
diet study with oleic and stearic acid fed mice gaining more weight than chow fed mice 
(Figure 3.3.2A).WT mice fed oleic diet gained fat mass from baseline and more than 
mice fed chow (Figure 3.3.2B). WT mice fed chow diet gained lean mass during the 
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study (Figure 3.3.2C). These results contradict the current dietary recommendations that 
all people consume a low to moderate fat diet. Even though the WT mice had no change 
in blood glucose levels, the increase in weight may predict increased frequency of health 
problems in older individuals.  
3.3.3 Oxygen consumption was unchanged by moderate fat diet enriched in stearic 
acid. 
Increases in resting metabolic rate or activity could result in lower blood glucose 
levels without concomitant weight loss. To assess these alternate explanations, I 
measured oxygen consumption as an indirect measure of metabolic rate of the mice after 
10 weeks on diet (Figure 3.3.3). All db/db mice had similar oxygen consumption 
measurements. The moderate fat diet enriched in stearic acid had no effect on oxygen 
consumption and, by extension, no effect on metabolic rate. Therefore, the lowered blood 
glucose measurements observed in the db/db mice fed the stearic versus oleic lower fat 
diet cannot be explained by alterations in metabolic rate.  
3.3.4 Fatty acids, especially oleic acid, accumulate in the livers of WT and db/db 
mice fed 17% kcal enriched in stearic acid and oleic acid.   
The liver is a major site of fatty acid accumulation in diabetic mice. Figure 3.3.4 
illustrates that the db/db mice fed the moderate fat diets containing either stearic acid or 
oleic acid had greater accumulation of fatty acid in the liver than wild-type mice 
(*p<0.05, n=5 per diet group per genotype), as previously documented for db/db mice 
(147). Surprisingly, both the oleic and stearic acid enriched diets, but not the chow diet, 
caused fatty acid accumulation in the liver of db/db mice. The increased fatty acid 
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accumulation in the liver, especially in the oleic acid fed db/db mice, is contradictory to 
the current opinion that an unsaturated fat diet is beneficial to the diabetic condition. 
3.3.5 After feeding a moderate fat diet, insulin tolerance is unchanged in WT and 
db/db mice. 
A reduction of fat absorption and lower blood glucose may also indicate improved 
insulin tolerance. High fat feeding has shown to exacerbate insulin resistance in the 
diabetic mouse model (7, 13, 14, 16, 28, 30). Diets rich in unsaturated fat, especially oleic 
acid, and low fat diets decrease insulin resistance (16, 136, 154, 163, 170). Surprisingly, 
WT and diabetic mice had no change from baseline in insulin response after ten weeks on 
diet (Figure 3.3.5 A and B). When plotted as a percent of fasting blood glucose 
measurement, WT mice had no difference in blood glucose measurements. However, the 
db/db mice fed oleic acid diet had higher blood glucose measurements after 10 minutes 
post insulin injection (Figure 3.3.5 C and D).  
3.3.6. Plasma insulin content was similar in all diet groups.  
Following the same course as insulin sensitivity, plasma insulin levels were also 
measured after 10 weeks on diet. If insulin sensitivity was unchanged, I expected that 
plasma insulin content would also be unchanged. Indeed, I found there were no 
differences among diet groups (Figure 3.3.6). This is a surprising result because 
moderate fat diets are the benchmark for improving insulin sensitivity thereby also 
lowering plasma insulin levels.  
 
61 
3.4 Discussion 
In this study, I investigated if a moderate fat diet enriched in stearic acid would 
provide protective benefits against the progression of type 2 diabetes. I found that mice 
on a moderate fat diet (17% kcal from fat) enriched in stearic acid, a saturated fat, had 
lower blood glucose levels than the standard chow fed db/db mice after ten weeks of 
feeding. Over the course of the diet study, db/db mice fed stearic acid enriched diet had 
increased blood glucose levels as compared to the baseline measurements, but when 
compared to chow and oleic fed mice, the db/db mice fed stearic acid had lower blood 
glucose levels. Normally, a decrease in weight and/or an increase in metabolic rate are 
linked to lower blood glucose levels. I found that after 10 weeks of moderate fat diet, 
weight and oxygen consumption did not change. Therefore, there was no concomitant 
change in weight or metabolic rate to account for the lower blood glucose levels in the 
db/db mice fed a moderate fat diet enriched in stearic acid. Interestingly, all mice, both 
wild-type and db/db, fed the experimental diets had increased accumulation of fatty acids 
in the liver. Since the mice fed the moderate fat diets all had similar body composition 
and oxygen consumption, the lower blood glucose level observed in the db/db mice fed 
the stearic acid diet may have been caused by a defect in absorption as I have previously 
reported with a 40% high fat diet enriched in stearic acid.  
The absorption of stearic acid in previous studies has depended on the form of the 
fat, either liquid or solid (10, 22, 75, 90). Diets enriched in a liquid form of stearic acid 
did not result in lowered fat absorption. However, the diets that were enriched in solid 
stearic acid resulted in decreased fat absorption (10). In this study, I used stearic acid in 
its natural, solid form, which would be the easiest form of stearic acid to incorporate into 
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a diet. This solid form also ensures that the fat is a pure form of stearic acid and is not 
contaminated with other fatty acids that may alter or influence our results. 
Most of the studies that involve stearic acid have been cardiovascular studies, but 
a few have evaluated the effects of saturated fats on type 2 diabetes. Berry, et. al. showed 
that mono-unsaturated fats have positive effects on insulin sensitivity in type 2 diabetes 
as long as saturated fats are kept at a minimum (16). In this study, I have shown that even 
a moderate fat diet enriched in oleic acid, a mono-unsaturated fat, promotes obesity and 
has no effect on insulin sensitivity. The oleic acid diet presented here closely aligns with 
the current USDA and AHA dietary recommendations of increasing mono-unsaturated 
fats, low saturated fats and decreased overall fat content in the diet (31).  
Oleic acid has been heralded in cardiovascular research for its ability to lower 
plasma cholesterol levels (25, 27). The mice fed oleic acid in this study had increased 
oleic acid accumulation in the liver. While liver fatty acid accumulation is not a direct 
measure of plasma lipoprotein content, it is a good indicator of plasma content since the 
liver is the storage depot for fatty acids and secretes lipoproteins (51). Accumulations of 
fatty acids in the liver have been linked to insulin resistance. In this study, I found that 
db/db mice fed a diet enriched in oleic acid did not lower blood glucose levels nor did it 
reverse insulin tolerance. Previous studies have reported diets rich in the unsaturated fat, 
oleic acid, have been shown to be beneficial in lowering blood glucose levels and 
reversing insulin intolerance in diabetic patients (16, 29, 50, 89, 90, 104, 124, 125, 154). 
This study indicates that, at least in db/db mice, oleic acid does not have the beneficial 
effects previous reported when administered in a single fat enriched diet. Additionally, 
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these results indicate that oleic acid may have detrimental effects by accumulating in the 
liver.  
In this study, the saturated fat, stearic acid, had beneficial effects on blood glucose 
levels and did not accumulate in the liver. These results support the argument that all 
dietary fats are not the same and stearic acid, a saturated fat, has beneficial effects. 
Cardiovascular studies have shown that stearic acid does not promote increases in plasma 
cholesterol levels. Whether or not this is due to defects in absorption of stearic acid is still 
unknown. However, the overall effect of stearic acid has been promising in this study as a 
potential dietary modification for treating type 2 diabetes.  
Limiting dietary fat content to less than 20% of the total kilocalories did not 
prevent an increase in blood glucose levels, a marker for the progression of type 2 
diabetes. The stearic acid fed db/db mice did not have a lower body mass than the 
baseline or chow fed diet group, but did have a decrease in lean mass. This decrease in 
lean mass may indicate that the mice were not eating enough food and/or were using 
breaking down muscle to maintain body weight. This is contradictory to the wild-type 
mice fed the stearic acid diet which increased lean mass from baseline. The oleic acid 
mice were not significantly greater in body mass at the end of the diet study than the 
chow group or the baseline measurement. Additionally, WT mice fed the experimental 
diets gained weight over the course of the diet revealing that a moderate fat diet enriched 
in one type of fat is not useful tool to halt the progression of type 2 diabetes in the db/db 
mouse model. 
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Figure 3.2.1: Experimental design for 17% moderate fat diet study. A total of 190 
mice, 95 wild-type mice and 95 diabetic (db/db) mice were used in these experiments. 
Mice were acclimated one week prior to the start of experimental diets and 
measurements. After the acclimation, five mice per genotype were measured for baseline 
(before diet initiation) control measurements and then euthanized for tissue processing. 
The remaining mice were assigned a diet group. Thirty mice of each genotype were 
assigned to the chow group, 30 were placed in the high fat diet enriched in stearic acid 
group, and the remaining 30 mice were placed in the high fat diet enriched in oleic acid 
diet group. After starting the diet, five mice per diet group per genotype were used for 
measurements and then euthanized for tissue collection every two weeks for the duration 
of the study with the final group euthanized at 24 weeks on diet. 
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Table 3.2.1: Dietary Components 
 
 Catalog Number Protein Carbohydrate Fat 
Chow TD. 2918 18.80 53.80 17.0 
17% kcal Stearic Acid TD. 03459 19.00 64.40 16.60 
17% kcal Oleic Acid TD. 09315 18.80 63.90 17.20 
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Table 3.2.2: 17% Diet Fat Composition 
Diet Chow Stearic Acid Oleic Acid 
% kcal from Fat 17.00 16.60 17.20 
 
% Stearic acid in fat 2.60 85.00 2.00 
% Oleic acid in fat 22.50 1.00 65.00 
% Other Essential Fatty Acids 74.90 14.00 34.00 
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Figure 3.3.1: A moderate fat diet enriched in stearic acid did not prevent an increase 
in blood glucose levels in diabetic mice. WT and db/db mice were fed a either a  
moderate fat diet enriched in stearic acid or oleic acid or were fed standard chow diet for 
10 weeks. After ten weeks on diet, all diabetic mice experienced an increase in blood 
glucose levels. Note no two week data is present due to fire alarm. ** p<0.01, *** 
p<0.0001; n=5. 
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Figure 3.3.2: A moderate fat diet enriched in stearic acid did not promote weight 
gain in db/db mice. After 10 weeks on diet, WT mice fed stearic acid and oleic acid 
diets had increases in weight gain (A. **p<0.01, n=5). In oleic acid fed WT mice had 
increases in fat mass from baseline. WT mice fed oleic acid also had increased fat mass 
compared to chow fed animals. (B. *p<0.05, n=5). All WT mice had increases in lean 
mass in all diet groups compared to baseline. Chow and stearic acid fed WT mice had 
higher increase in lean mass compared to oleic acid fed WT mice. Db/db mice fed stearic 
acid had lost lean mass after 10weeks of diet compared to baseline and chow and oleic 
acid diet groups (C. *p<0.05, **p<0.01, ***p<0.001, n=5). 
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Figure 3.3.3: A moderate fat diet does not alter oxygen consumption. Oxygen 
consumption was not changed by any diet. WT and db/db mice showed a slight and 
insignificant variation in oxygen consumption, as expected.  
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Figure 3.3.4: Liver Fatty Acid Accumulation.  Fatty acids accumulated in the livers of 
both the WT and db/db mice fed the experimental diets. Interestingly, in the livers of both 
WT and db/db mice, oleic acid was the major fat that accumulated, regardless of diet. 
Note the difference in ordinate scale in panel A and B. * p<0.05, n=5 mice. 
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Figure 3.3.5: Insulin Tolerance Test. Insulin tolerance remained unchanged in both WT 
(A) and db/db mice after ten weeks on diet (B).  When blood glucose was plotted as 
percent of fasting blood glucose, no differences were observed. Interestingly, in WT mice 
(C), all diet groups had lower percent of baseline blood glucose levels as compared to 
baseline. Db/db mice also showed a similar trend. Db/db baseline measurements were 
higher in early time points (0-10 minutes after injection) than the diet groups (D).  
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Figure 3.3.6: Plasma insulin content did not change with a moderate fat diet. 
Insulin content was measured by ELISA and no significant difference was found between 
diet groups or genotypes. * p<0.05. 
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Chapter 4: A high fat diet enriched in stearic acid partially reversed hyperglycemia 
in db/db mice with prolonged hyperglycemia. 
4.1 Introduction 
In humans, Type 2 Diabetes Mellitus is more likely to be caused by obesity and 
lifestyle choices than genetic mutation such as the case in db/db mice. In humans, 
mutations in either the leptin protein (ob/ob) or the leptin receptor (db/db) are rare and 
are not sufficiently frequent to explain the increased rate of type 2 diabetes incidence in 
the last 50 years. Dietary influences and obesity are the largest risk factors in the 
development of type 2 diabetes. Most cases of type 2 diabetes can be directly linked to 
obesity and evaluating the amount and types of fat in the diet can offer an early treatment 
for both obesity and type 2 diabetes.  
Clinically, no treatment of diabetes begins until clinical manifestations of the 
disease are present, well after hyperglycemia is established. In many cases, uncontrolled 
hyperglycemia may be present for months to years before diagnosis and treatment begin. 
Therefore, I examined if our experimental diets would be beneficial in slowing and 
reversing the symptoms of type 2 diabetes if started after diabetic symptoms were well 
pronounced. 
I already observed the slowed progression of diabetic symptoms by the 40% kcal 
high fat stearic acid enriched diet in db/db mice. Thus, I tested if dietary stearic acid 
could rescue mice with established severe hyperglycemia. Since I already determined that 
db/db mice fed chow diet for ten weeks have a two fold increase in blood glucose levels 
from baseline, I maintained mice on chow diet before switching them to one of our 
experimental diets. In this study, I tested all four of our experimental diets in order to 
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determine: 1) if stearic acid affects blood glucose levels of mice with established 
hyperglycemia; 2) if there is a dose effect in the administration of stearic acid. Wild-type 
and db/db mice were fed the chow diet for six, eight, or ten weeks to establish 
hyperglycemia. The mice were then switched to 40% stearic acid, 17% stearic acid, 40% 
oleic acid, or 17% oleic acid diet for an additional six weeks of feeding. At the initiation 
of the diet and at the conclusion of the study, I measured fasting blood glucose, weight, 
and plasma insulin levels.  
4.2 Materials and Methods 
4.2.1 Animals 
 Wild-type, age-matched, male C57BLKS/J (WT, n=72) and BKS.Cg-Dock7
m
 +/+ 
Lepr
db
/J (db/db, n=72) were purchased from The Jackson Laboratory (Bar Harbor, 
Maine) at four weeks of age.  Upon receipt they were acclimated for one week to baseline 
conditions of a 12-hr light/dark cycle at 25°C on an ad libitum diet of commercially 
available standard rodent chow diet (2018 Teklad Global 18% Protein Rodent Diet; 
Harlan Laboratories, Madison, Wisconsin). At five weeks of age, I weighed the mice, 
gave each an ear tag, drew blood for a baseline blood glucose measurement, and 
randomly assigned each mouse to a diet group (n=8 mice per group per genotype). The 
diets were the standard chow diet and four experimental diets (40% kcal stearic acid diet 
Harlan Teklad TD.04096, 40% kcal oleic acid diet TD.09055, 17% kcal stearic acid diet, 
Harlan Teklad TD.03459, 17% kcal oleic acid diet TD.09315). Mice were fed ad libitum. 
All mice were fed standard chow diet until 6, 8, and 10 weeks of age to establish 
hyperglycemia. The mice were then switched to one of the four experimental diets for six 
additional weeks. Figure 4.2.1 outlines the experimental design for this study. Animal 
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care and housing were conducted according to the NIH Guide for the Care and Use of 
Laboratory Animals and all experiments were approved by the Institutional Animal Care 
and Use Committee at the University of Kentucky. 
4.2.2 Diets 
Table 4.2.1, 4.2.2, and 4.2.3 list the nutritional value and composition of each diet 
used in this study. The stearic and oleic acid diets used in this study contained similar 
percentages of protein and carbohydrate whereas chow diet contained slightly more of 
total kcal from protein and 60% total kcal from carbohydrates. The fat content of each 
diet was unique.  The experimental diets were custom made by Harlan Teklad using a 
modified TD.03459 diet. A Harlan Teklad nutritionist calculated all dietary nutritional 
values. 
4.2.3 Glucose Measurements 
Blood glucose was measured at the initiation of the diet (Baseline) and again at 
the end of the diet study. Mice were weighed and then fasted for four hours in a clean 
cage prior to testing. Fasting blood glucose was measured by tail prick with a 
commercially available glucometer and test strips (One Touch Ultra Glucose Monitoring 
Kit, Lifescan, Milpitas, California). 
4.2.4 Body Weight 
Weight was measured in conscious mice at the initiation of diet and at the 
completion of the diet study (6, 8, 10week groups) using a standard portable laboratory 
scale (Ohas, Model HH320, Fisher Scientific, Pittsburgh, Pennsylvania).  
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4.2.5 Insulin ELISA 
 Collected blood from fasted animals (4 hour fast) was allowed to clot for 20 
minutes in a vacutainer and centrifuged at 1500 X g for 10 minutes to isolate serum. 
Serum was then snap-frozen and stored at -80⁰C until analyzed. Plasma insulin levels 
were measured using a commercially available mouse/rat insulin ELISA (Millipore, 
Billerica, Massachusetts) and reported in ng/mL.  
4.2.6 Data Analysis  
 Values are depicted as mean + standard error and considered significant if p < 
0.05. Data were statistically analyzed using two-way ANOVA with Bonferroni correction 
or one-way ANOVA with Dunnett’s post hoc test when appropriate using GraphPad 
Prism 5.01 for Windows (GraphPad Software, San Diego, California). NIS-Elements 3.0 
(Nikon Instruments, Elgin, Illinois) was used for islet area and staining analysis. 
4.3 Results 
4.3.1. Blood glucose levels in diabetic mice switched to a high fat diet enriched in 
stearic acid are lower than before the mice started the experimental diet. 
Since I have already determined that db/db mice fed chow diet for ten weeks have 
a two fold increase in blood glucose levels from baseline, I designed a rescue study to 
examine the effects of stearic acid and oleic acid on blood glucose levels after 
hyperglycemia is established, similar to the onset of treatment in human type 2 diabetes. 
WT and db/db mice were fed the chow diet for 6, 8, or 10 weeks to establish 
hyperglycemia. The mice were then switched to 40% stearic acid, 17% stearic acid, 40% 
oleic acid, or 17% oleic acid diet for an additional six weeks. Blood glucose levels were 
tested at the initiation of the diet (Chow) and the cessation of the diet study. Wild-type 
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mice switched from the chow diet to any of the experimental diets maintained normal 
blood glucose levels regardless of how long they were fed chow diet (Figure 4.3.1A, B, 
C).   
Db/db mice fed chow for 6 weeks and then switched to 17% oleic acid diet had 
decreased blood glucose levels compared with the baseline chow measurement (Figure 
4.3.1A). Db/db mice switched to 17% stearic acid, 40% oleic acid, and 17% oleic acid 
diets continued to have elevated blood glucose levels after switching from chow 
following 8, and 10 weeks of feeding (Figure 4.3.1A, B, C). Db/db mice switched to 
17% stearic acid diet after 6 weeks of chow feeding had decreased blood glucose 
compared to the chow baseline, 17% oleic acid, and 40% oleic acid fed mice. 
Additionally, the 40% stearic acid diet slowed and even reversed the progression of type 
2 diabetes in diabetic mice with hyperglycemia regardless of time on chow.  
4.3.2. Body weight was not changed by rescue diet intervention. 
Wild-type mice fed chow diet for 6 weeks and then were switched to 40% stearic 
acid diet had significantly decreased body weight compared to all other diet groups and 
the baseline measurements (Figure 4.3.2A). After 8 weeks of chow feeding and 
switching to 40% stearic acid diet, wild-type mice had lower blood glucose than 17% 
stearic acid, 17% oleic acid, and 40% oleic acid fed mice but not lower than baseline 
glucose measurements (Figure 4.3.2B). No change in body weight was detected in mice 
that were fed chow diet for 10 weeks before being switched to 40% stearic acid diet 
(Figure 4.3.2C).  
Diabetic mice fed chow diet for 6 weeks and then switched to 17% oleic acid and 
40% oleic acid diets had increases in body weight as compared to baseline weight 
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measurement (Figure 4.3.2A). After 8 weeks of chow diet and then switching to 40% 
stearic acid diet, db/db mice had a significant decrease in body mass compared to 17% 
stearic acid, 17% oleic acid, and 40% oleic acid diets, but no different from baseline 
measurement (Figure 4.3.2.B). Importantly, db/db mice switched from chow diet to 40% 
stearic acid diet after 10 weeks of chow feeding had a large and significant decrease in 
blood glucose levels even though their body mass did not decrease significantly 
compared to mice fed chow diet (Figure 4.3.2C). Db/db mice fed 17% stearic acid, 17% 
oleic acid, and 40% stearic acid diets had no significant changes in body weight (Figure 
4.3.2C).  
4.3.3. Plasma insulin was not changed by rescue diet. 
 Plasma insulin content was measured only in the 10 week study. There were no 
significant differences in plasma insulin content in any of the diet groups or genotypes.   
4.4 Discussion 
Dietary interventions for treating hyperglycemia have been relatively ineffective 
at maintaining lowered blood glucose for a significant duration of time. Most of these 
dietary interventions focus on weight loss as a means to also decrease blood glucose. In 
most clinical manifestations of type 2 diabetes, patients are often hyperglycemic for long 
periods of time (months to years) before seeking treatment. Diet induced obesity is linked 
to high intake of dietary fat. Combining a high fat diet with hyperglycemia may 
exacerbate hyperglycemic conditions. In this study, I examined whether a high fat dietary 
intervention in which I modified the type of fat consumed could lower blood glucose 
levels in mice with established and severe hyperglycemia. I found that a high fat diet 
(40% kcal from fat) enriched in stearic acid reduced blood glucose levels without a 
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change in weight. However, a low fat diet (17% kcal from fat) enriched in stearic acid 
had no effect on blood glucose levels in db/db mice with established hyperglycemia. 
Similarly, mice fed a low fat diet with mixed fats (normal chow diet) and mice fed a high 
fat diet enriched in oleic acid, a mono-unsaturated fat, did not reverse or slow the 
progression of hyperglycemia. The mice fed these diets continued to have high blood 
glucose levels. These data indicate that a high-fat diet enriched in stearic acid may be a 
suitable dietary intervention for treating hyperglycemia, especially in patients who have 
trouble adhering to a low fat diet.  
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Table 4.2.1: Dietary Components 
 Catalog Number Protein Carbohydrate Fat 
Chow TD. 2918 18.80 53.80 17.0 
40% kcal Stearic Acid TD. 04096 17.80 42.20 40.0 
40% kcal Oleic Acid TD. 09088 17.50 41.50 41.0 
17% kcal Stearic Acid TD. 03459 19.00 64.40 16.60 
17% kcal Oleic Acid TD. 09315 18.80 63.90 17.20 
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Table 4.2.2: 40% diet composition 
Diet Chow Stearic Acid Oleic Acid 
% kcal from Fat 17.00 40.00 41.00 
 
% Stearic acid in fat 2.60 86.00 2.00 
% Oleic acid in fat 22.50 <1.00 64.00 
% Other Essential Fatty Acids 74.90 13.00 34.00 
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Table 4.2.3: 17% diet composition 
Diet Chow Stearic Acid Oleic Acid 
% kcal from Fat 17.00 16.60 17.20 
 
% Stearic acid in fat 2.60 85.00 2.00 
% Oleic acid in fat 22.50 1.00 65.00 
% Other Essential Fatty Acids 74.90 14.00 34.00 
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Figure 4.2.1: Experimental design for rescue diet study. In a separate but parallel 
study to examine the effects of dietary stearic acid on adult mice with severe and 
prolonged hyperglycemia, db/db and WT mice were aged to 6 weeks, 8 weeks, and 10 
weeks of age on standard chow diet. These mice were then switched to one of the four 
experimental diets: 17% kcal stearic acid, 17% kcal oleic acid, 40% kcal diet stearic acid, 
or 40% kcal oleic acid and maintained on these experimental diets for 6 weeks. Similar 
parameters from the previous studies were measured: blood glucose, weight, and body 
composition.  
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Figure 4.3.1: A high fat diet enriched in stearic acid decreases blood glucose levels in 
db/db mice with pre-existing hyperglycemia. A. 6 weeks chow  6weeks 
experimental diet.  B. 8 weeks chow  6 weeks experimental diet. C. 10 weeks chow  
6 weeks experimental diet. * p<0.05, * p<0.01, *** p<0.001, n=8 per group. 
  
 
88 
 
Figure: 4.3.2: Body mass during rescue diet study. A. 6 weeks chow6 weeks 
experimental diets. db/db mice switched from a chow diet to a 17% and 40% fat diet 
enriched in oleic acid have increased weight compared to baseline (chow). Both WT and 
db/db mice fed 40% stearic acid diet had decreased body weight after B. 8 weeks 
chow6 weeks experimental diets. WT and db/db mice 40% stearic acid diet had lower 
body mass than other diet groups but not lower than baseline weight. C. 10 weeks 
chow6 weeks experimental diets. Db/db mice fed 40% oleic acid diet had significantly 
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higher body mass than db/db mice fed any other diet and higher than baseline. *p<0.05, 
**p<0.01, ***p<0.001 and n=4-8 per diet group per genotype.  
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Figure 4.3.3: 40% high fat diet enriched in stearic acid or oleic acid has no effect on 
plasma insulin levels. Plasma insulin levels of mice placed on 40% high fat diets at ten 
weeks of age were measured after 6 weeks on diet. There were no differences in plasma 
insulin levels in any group of mice.   
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Chapter 5: Discussion 
 The purpose of this research was to test the hypothesis that a high fat diet 
enriched in stearic acid slows the progression of type 2 diabetes in a db/db mouse model. 
The work presented in this dissertation supports my global hypothesis that stearic acid 
has protective effects in slowing the progression of type 2 diabetes. These findings are 
novel in the field of type 2 diabetes dietary fatty acid research and may improve upon 
current dietary recommendations for diabetes patients. 
Chapter 2 examined the effects of a high fat diet enriched in stearic acid on the 
progression of type 2 diabetes in a diabetic mouse model. Using this murine model and 
experimental diet, evidence was provided that the progression of type 2 diabetes was 
slowed when mice were fed a high fat diet enriched in stearic acid during the diet study. 
Additionally, the db/db mice were protected from severely elevated blood glucose levels, 
a major factor in pancreatic beta cell failure; this protection was unrelated to weight loss 
(100). This supports the hypothesis that the effects of stearic acid are due to alterations in 
fatty acid absorption in the gut. The mechanism by which stearic acid has decreased 
absorption is unknown. However, the decreased absorption does support the idea that 
stearic acid is beneficial in slowing the progression of type 2 diabetes. In this study, I 
found that a high-fat diet enriched in stearic acid, but not a high-fat diet enriched in oleic 
acid, a monounsaturated fat, was able to lower blood glucose levels in db/db mice 
without a concomitant change in body weight, a novel finding in diabetic diet studies. 
In Chapter 3, I asked whether stearic acid has beneficial effects in a low fat diet, a 
regimen more closely aligning with current dietary recommendations (~20% kcal from 
fat). Lowering the fat content in the experimental diets from 40% kcal from fat to 17% 
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kcal from fat significantly impaired the effectiveness of the diet as compared to the 40% 
kcal experiments. Blood glucose levels in wild-type mice did not differ from those of 
db/db mice on the moderate fat diets. Db/db mice fed chow, stearic acid and oleic acid 
enriched diets all and increased blood glucose levels. This result indicates that stearic 
acid has a dose-dependent effect on blood glucose levels and additional studies are 
warranted to investigate the amount of fat absorbed in this moderate fat diet. Since stearic 
acid has no detrimental effect on cholesterol levels, it may be incorporated into the diet as 
a treatment for lowering blood glucose levels without concern for cardiovascular 
complications. I found that only a high-fat diet enriched in stearic acid was able to control 
hyperglycemia in db/db mice. Mice fed moderate-fat diets (17% kcal from fat) enriched 
in stearic or oleic acid were not as fat as the high-fat fed mice, but had blood glucose 
measurements that were higher than their baseline measurements. 
Chapter 4 extended the hypothesis that stearic acid has beneficial blood glucose 
lowering effects and focused on treating mice that had established severe hyperglycemia.  
I designed a ‘rescue’ diet study in which wild-type and db/db mice were fed chow diet for 
6, 8, or 10 weeks before being switched to one of the experimental diets. I confirmed the 
results from the first and second experiments: a high-fat diet (40%kcal from fat) lowered 
blood glucose levels without a decrease in weight; a moderate fat diet (20%kcal fat) did 
not lower blood glucose levels in db/db mice. Further I found that only a diet enriched in 
stearic acid, not the unsaturated fat oleic acid, was able to lower blood glucose levels. 
The ability of a stearic acid enriched high fat diet to slow the progression of diabetes and 
reverse hyperglycemia in db/db mice argues that risks and benefits of fats in the diet 
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depend on the species, rather than the chemical class, of fats ingested. The beneficial 
effect of stearic acid appears to be associated with a decreased absorption of dietary fat. 
5.1 Future Directions 
My first and second aims were designed to determine if stearic acid could lower 
blood glucose levels in diabetic mice and if there was a dose-dependent effect of stearic 
acid on blood glucose levels. I used direct dietary supplementation of stearic acid and 
evaluated the effects on the disease state to determine if a high-fat diet enriched in stearic 
acid, a saturated fat, slows the progression of type 2 diabetes in db/db mice. Diets 
enriched in saturated fats have been labeled as detrimental to overall health and allegedly 
linked to cardiovascular events. Previous studies have reported that dietary stearic acid 
has minimal effects on plasma cholesterol levels, unlike the saturated fat palmitic acid, 
another common dietary saturated fat, which increases LDL cholesterol. Stearic acid may 
be used as a dietary treatment option for type 2 diabetes without concern for detrimental 
cardiovascular effects. 
In the work for the first and second aims, I found there was, in fact, a dose 
dependent effect of stearic acid. Db/db mice fed stearic acid had lower blood glucose 
levels when fed a high fat diet (40% kcal from fat) enriched in stearic acid but not when 
fed a 17% kcal moderate fat diet enriched in stearic acid. Stearic acid may have worked 
more efficiently at lowering blood glucose levels in the high fat diet than in the moderate 
fat diet because the amount of fat in the diet was able to overwhelm the fat transport 
system.  
Stearic acid poses a unique problem for the fat emulsification, hydrolysis, and 
absorption pathways. Stearic acid, like many saturated fats is solid at room temperature 
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(10). Unlike saturated fats that have been tested in previous dietary studies, solid stearic 
acid is not emulsified or hydrolyzed efficiently by endogenous agents (109). To be 
absorbed from the diet, fats must be emulsified by bile salts made by the liver and stored 
in the gallbladder (143). The pancreas makes and secretes pancreatic lipase which 
enzymatically cleaves the fatty acids tails from the glycerol (143). Lipase, however, is 
water soluble and can only cleave fatty acids that are near the edge of the emulsion 
micelle (173). Although there is a large amount of pancreatic lipase in the small intestine 
ready to hydrolyze fats, it is also easy to visualize how a high-fat diet easily overwhelms 
the emulsification and hydrolytic processes. Ingesting large amounts of fat, especially 
saturated fat, requires large amounts of bile to complete emulsify the fats. A disruption in 
the fat and bile ratio leaves fat globules intact rather than emulsified in micelles (80, 
178). The intact fat globules are not absorbed across the intestinal wall and instead move 
through the digestive tract for excretion. I have shown that stearic acid is not well 
absorbed and is excreted in the feces of the mice fed a diet enriched in stearic acid. 
Importantly, the mice fed a high-fat diet enriched in stearic acid excreted more fat in the 
feces than those mice fed a high-fat diet enriched in oleic acid, an unsaturated fat that is 
emulsified and hydrolyzed efficiently (77).  
This demonstration of manipulation of the fat absorption pathway is not novel. 
The drug orlistat works by blocking pancreatic lipase thereby decreasing digestion and 
absorption of fat and increasing excretion (79). This mechanism of using a fat to block its 
own absorption and act in a manner similar to well defined pharmaceutical, orlistat, is 
novel and may have future promise in dietary treatments of type 2 diabetes instead of 
reliance on pharmaceuticals. 
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Similarly, stearic acid did not provide all the caloric value of the diet. 60% of the 
kilocalories in the diet came from protein and carbohydrate. The poor absorption of 
stearic acid from the gut eliminates the fat from providing a sufficient primary fuel 
source. Thus, the mice must utilize the remainder of the diet, the protein and 
carbohydrates, for fuel, effectively lowering the caloric content without restricting food 
consumption. The decrease in blood glucose levels did not occur until two weeks after 
the diet intervention was started indicates that the diet intervention had a compensatory 
time, during which the body, most notably the gut, was adjusting to the change in nutrient 
supply. This, together with the increase in fecal fat excretion and low liver accumulation 
of stearic acid, supports studies that have shown stearic acid may change the gut 
microflora (42, 158).  The gut microflora, the resident bacteria of the gut, is also involved 
in metabolizing diet contents. The microflora constituents can change to adjust to the 
dietary demands placed upon it. Increasing the fat content will demand for more fat-
metabolizing gut bacteria and less carbohydrate-metabolizing bacteria (32, 33). 
Examining the constituents of the gut microflora may indicate how mice were utilizing 
the diets administered to them.  
Recall that carbohydrates are the preferred fuel source and can be easily 
metabolized; however, proteins, like fat, are not as efficiently metabolized. To test if the 
mice were utilizing the other diet components in place of the fat, one may measure the 
waste product from the metabolism of protein: urea (97). Elevated levels of urea in the 
liver and urine of db/db mice on stearic acid diet compared to WT and db/db mice on 
non-stearic acid diets would indicate that the stearic acid fed mice were using proteins as 
a primary fuel source and were able to maintain their body weight by using the 
 
96 
components in the diet more efficiently than the db/db mice fed oleic acid and chow diets 
that contained fat that was easily absorbed.     
Though I found that stearic acid was not well absorbed by the mice, there is little 
doubt that the mice are absorbing some of the stearic acid from the diet. Stearic acid may 
have effects on the insulin release signaling cascade. Stearic acid, similar to other long-
chain fatty acids, acts as a cellular signaling molecule in the insulin release pathway (69, 
70). The G-protein coupled receptor, GPR40, which is expressed in the pancreatic beta 
cells, plays a role in potentiating the insulin release pathway and has a fatty acid binding 
domain (26, 95, 167). Stearic acid has the potential to bind to the fatty acid binding 
domain of GPR40 thereby activating the receptor and downstream signaling cascade 
culminating in insulin granule fusion and insulin release from the pancreatic beta cells.  
Given the mechanism outlined above, the input of stearic acid on the GPR40 
pathway should be evaluated. Steneberg et al. (164) previously showed that GPR40 
knockout mice were resistant to fatty-acid modulation of insulin secretion and 
normoinsulinemic. Additionally, GPR40 overexpressing transgenic mice were 
hypoinsulinemic and diabetic (56). My data point toward fatty-acid potentiation of insulin 
secretion and intense contribution of fatty-acid to insulin resistance though the GPR40 
pathway. 
Steneberg et al. did not control the specific fats in the diet; mice were fed either a 
high-fat, mixed fat diet or a control diet (164). To evaluate the effects of stearic acid on 
GPR40 activation, the Steneberg study could be replicated to include the stearic acid 
presented in this work. Measurements of plasma insulin, glucose tolerance and insulin 
tolerance would evaluate the effect of stearic acid on the GPR40 pathway. If stearic acid 
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influenced the GPR40 pathway, one would observe an increase in plasma insulin levels, 
no glucose or insulin intolerance. If stearic acid did not contribute to the GPR40 pathway, 
insulin levels would increase, and both glucose and insulin tolerance would decrease. 
Additionally, GPR40 content in the pancreas should also be examined. If there were no 
change in the amount of GPR40 present in the islets from WT mice, overactivation of 
GPR40 would not be likely. 
Similarly, caveolin-1, a membrane bound protein found abundantly in the 
pancreatic beta cells that has a role in insulin secretion, acts as a gate in the insulin 
granule fusion and release pathway (138). Insulin granule fusion with the plasma 
membrane is controlled by the  small Rho family GTPase, cdc42,  in complex with 
VAMP2, and by caveolin-1 (138). When associated with caveolin-1, the granules do not 
fuse with the membrane (138). However, upon glucose stimulation, caveolin-1 releases 
the inhibition on the cdc42-VAMP2, and the insulin granules fuse with the membrane to 
release insulin (138). Moreover, a fatty acid, like stearic acid, could bind to caveolin-1, 
and, via the cdc42 pathway, increase insulin secretion by releasing the inhibition of 
caveolin-1 on the insulin granules (169).  
In the pancreatic islets, fatty acids, such as stearic acid, may bind to caveolin-1 
and move the fatty acid into the cell while simultaneously releasing the inhibition from 
insulin granules. This would increase pancreatic islet fatty acid content and increase 
insulin exocytosis. To test modulation of the insulin granule pathway by stearic acid, a 
few experiments would be effective. Isolated pancreatic islets from diet treated WT and 
db/db mice would be measured for fatty acid content by GC/MS. Next, another set of 
islets would be incubated with stearic acid in the culture media. The culture media would 
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be collected and analyzed for secreted insulin content and fatty acid by ELISA and 
GC/MS, respectively. Additionally, the islets would need to be homogenized and 
analyzed for stearic acid content. If insulin content of the culture media in the islet from 
the diabetic animals increases and stearic acid content decreases, stearic acid may 
positively modulate the insulin secretion pathway by removing the inhibition of caveolin-
1 on the insulin granules. Simultaneously, stearic acid may bind to caveolin-1 for 
transport into the islets resulting in a higher stearic acid concentration inside the 
pancreatic islets. Removal of fatty acids from the culture media would ameliorate this 
effect.  
In only one cohort I observed a decrease in weight in the db/db mice fed stearic 
acid. The maintenance of weight coupled with lower blood glucose is contradictory to 
most diabetic dietary intervention studies (45, 104). The experimental diets, both stearic 
acid and oleic acid diets, had similar compositions of protein and carbohydrate 
components and only differed in the type of fat, not the amount of fat, that was added. 
The maintenance of weight in the stearic acid diet group may indicate better glucose 
uptake by the skeletal muscle. 
Another mechanism by which stearic acid may have lowered blood glucose levels 
in the diabetic mice is through improvements in skeletal muscle uptake of glucose. 
Increasing glucose uptake into the skeletal muscle would decrease blood glucose levels 
(11, 52, 128). Glucose uptake into the skeletal muscle is driven by the activation of the 
insulin receptor. Insulin binding its receptor activates a signaling cascade that moves 
more GLUT-4 glucose transporters onto the cell membrane (44). Glucose moves through 
the glucose transporter and into the muscle cell (106). Caveolin-1 also plays a role in 
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insulin receptor activation. Previous studies have reported that insulin can activate 
caveolin-1 by phosphorylation at tyrosine 14 (157). Activation of caveolin-1 has been 
reported in increase GLUT-4 translocation (36, 120). My results indicated that db/db 
mice fed a high fat diet enriched in stearic acid did not have decreased plasma insulin 
levels; therefore, the circulating insulin could bind to its receptor activating caveolin-1 to 
promote enhanced GLUT-4 translocation. Additionally, the increased level of circulating 
fatty acids may promote additional caveolin-1 to the plasma membrane. Additional 
caveolin-1 on the membrane may have the potential to further increase the translocation 
of GLUT-4 to the skeletal muscle membrane. An increased amount of caveolin-1 would 
also result in an increase in lipid deposit in the muscle cell. Immunohistological staining 
for GLUT-4 on the muscle cell surface as well as skeletal muscle lipid content identified 
by Oil Red O staining would indicate if stearic acid is promoting lower blood glucose 
levels by increasing glucose transport into the skeletal muscles.  
The work presented in this dissertation supports my global hypothesis that stearic 
acid has protective effects in slowing the progression of type 2 diabetes. These findings 
are novel in the field of type 2 diabetes dietary fatty acid research and may improve upon 
current dietary recommendations for diabetes patients. 
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Keystone Symposium, Keystone, CO. January 2011.  
 
Reeves, VL, Thomas, CM, McClintock, TS, Randall, DC. 2011. A link between lower 
blood glucose and dietary stearic acid intake in diabetic mice. University of Kentucky 
Endowed Professor Program Day, Lexington, KY.  March 2011 
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Reeves, VL, Randall, DC. 2011. Dietary Fat and Type 2 Diabetes: The Good, the Bad 
and the Ugly. Barnstable-Brown Diabetes and Obesity Research Day, Lexington, KY. 
May 2011 
 
Reeves, VL, Randall, DC. 2011. A Diet Enriched in Stearic Acid Slows the Progression 
of Type 2 Diabetes in Mice. Gill Heart Research Day, Lexington, KY. October 2011 
 
Awards and Honors 
2007-2012 Graduate Research Assistantship, Integrated Biomedical Sciences 
Program, University of Kentucky 
2009  University of Kentucky Graduate School Travel Award  
2011 University of Kentucky Cardiovascular Training Grant T-32 (awarded but 
declined) 
 
Positions 
2010- Present  Adjunct Faculty  
Bluegrass Community and Technical College, Lexington, KY 
BIO 130: Aspects of Human Biology lecture instructor, BIO 137: 
Anatomy and Physiology I lecture and laboratory instructor, BIO 139: 
Anatomy and Physiology II, laboratory instructor 
2009-2010 Student Leader  
University of Kentucky, Department of Physiology Teaching, Education 
and Mentoring (TEaM). Student run organization that focuses on 
providing an environment to explore career options by inviting speakers in 
all science-based fields, hosting workshops to complete teaching 
portfolios and curriculum vitas, and host discussions about mentoring 
concerns. 
 
Society Memberships 
2007 - Present  American Association for the Advancement of Science (AAAS) 
2010 - Present  American Diabetes Association 
2012 – Present American Heart Association 
2011 – Present American Physiological Society  
2011 – Present Graduate Women in Science, Bluegrass Chapter (Beta Chi) 
